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Abstract 
 
Aims 
This study aimed to investigate how various genetic variants affect acute coronary 
syndrome (ACS): its subtype and the prognosis. More precisely, its objectives were to 
describe the characteristics of a Finnish cohort of consecutive angiography patients and to 
evaluate the importance of clinical risk factors and genetic risk scores (GRS) in predicting 
the ACS prognosis. Additionally, genetic differences were sought between patients with 
non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial 
infarction (STEMI). The newly discovered NSTEMI risk variant was studied for effects 
on prognosis, clinical risk factors and other manifestations of atherosclerosis.  
 
Material and methods 
Studies I to IV are based on the Corogene cohort, consisting of 5 294 consecutive patients 
who underwent coronary angiography between 2006 and 2008. The patients with ACS or 
prior myocardial infarction (MI) were genotyped. Additionally, genotyped individuals 
from Tampere Acute Coronary Syndrome Study (TACOS) (Study III) and FINRISK 
cohorts (Studies III-IV) were included to further test the findings discovered of the 
Corogene Study.  
Study I was an observational cohort study of all the 5 294 consecutive coronary 
angiography patients included in the Corogene Study. It described the risk factor profiles, 
disease stability and severity, and the revascularization strategy of all these patients. Study 
II elucidated the recurrence rate and the mortality from coronary artery disease (CAD) in 
the 2 090 ACS patients during a median 5.5-year follow-up, and clinical factors affecting 
their prognosis. The GRS of 47 previously known CAD risk variants was formed and 
tested for association with recurrent ACS and CAD mortality. Clinical risk factors were 
studied for association with the GRS47. Patients with MI were selected for Study III, a 
genome-wide association study (GWAS), to discover new genetic variants conferring risk 
specifically for NSTEMI or STEMI. The variants passing a pre-defined statistical 
significance threshold were chosen for replication in the TACOS and FINRISK cohorts. In 
Study IV, data of all the genotyped ACS patients served for analysis of clinical 
characteristics and comorbidities associated with the variant discovered in the GWAS of 
Study III, with special emphasis on the variant’s effect on the prognosis and on incidence 
of peripheral artery disease (PAD).  
 
Main results 
The most common reason for coronary angiogram in the Corogene Study during the study 
period was ACS (2 090, 39%). Almost one-fourth of the patients (1 207, 23%) had no 
signs of obstructive CAD in coronary angiography. About half of all patients (2 854, 54%) 
were finally revascularized.  
Of the ACS patients, 263 (12.6%) had recurrent ACS, 455 (21.8%) died during the 
follow-up, and 259 (12.4%) had a CAD-related cause of death. The GRS47 was found 
associated with recurrent ACS, independent of clinical factors. When added to a risk-
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prediction model of traditional risk factors and patient characteristics, however, the 
GRS47 did not improve the classification clinically significantly. Among ACS patients, 
the GRS47 correlated inversely with STEMI and with smoking. GWAS revealed genetic 
variants at a locus near 1p13.3, including rs656843, to be associated nominally with 
NSTEMI. Finally, rs656843 additionally showed association with PAD incidence in the 
ACS patients, but had no effect on recurrence of ACS or on survival during the follow-up. 
In the FINRISK cohort, which included healthier and younger individuals, no association 
could be demonstrated with PAD.   
 
Conclusions 
A GRS combined of CAD risk variants was associated with recurrent ACS in a Finnish 
ACS population. As it did not improve the accuracy of prediction by clinical factors, the 
GRS has thus not yet proven useful in clinical practice. Smoking, having an inverse 
association with the GRS, may outweigh the genetic predisposition to CAD. 
The inverse correlation of GRS with STEMI and thus positive correlation with 
NSTEACS, the finding of a genetic variant linked nominally to NSTEMI, and the fact that 
patients with NSTEMI and STEMI present with different clinical risk-factor profiles 
suggest that these two ACS subtypes may have somewhat different etiologies. The genetic 
variant conferring the risk for NSTEMI was also associated with PAD in ACS patients. 
The heterogeneity in PAD phenotypes and genetics may explain why the association could 
not be shown in a general population sample but only in a selected cohort of ACS patients.  
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1. Introduction 
Coronary artery disease (CAD), acute coronary syndromes (ACS), and other conditions 
related to atherosclerosis are leading causes of death in developed countries. Therefore, 
the search for risk factors has also been thorough. Known clinical risk factors for the 
different manifestations of cardiovascular disease (CVD), such as CAD, peripheral artery 
disease (PAD), ischemic stroke, and aneurysms of the aorta are overlapping, and the 
importance of one risk factor may vary across the disease subtypes. The most important 
and widely acknowledged risk factors are hypertension, dyslipidemia, diabetes mellitus, 
tobacco smoking, and genetics. While knowledge of the risk factors has increased, and 
both prevention and treatment of CAD and ACS have developed, CAD incidence and 
mortality have begun to decrease.  
The gold standard in imaging CAD is invasive coronary angiography. Percutaneous 
coronary intervention (PCI) performed in the same session as coronary angiography is a 
cornerstone of ACS treatment. In stable CAD, in patients with severe symptoms, the 
angiography result guides the choice of revascularization strategy, and in patients with 
chest pain of unknown cause, the angiography may provide the diagnosis. In recent years, 
other methods for CAD imaging have also been rapidly evolving.  
The incidence of CAD cannot be explained by environmental factors only; family 
history also matters. The genetics of CAD has been of great interest recently. During the 
last decade major findings have emerged with many CAD-related SNPs found. To date, 
more than 50 genetic variants have been linked to CAD. Of note, most of them do not act 
through any known clinical risk factor, but independently, or their mechanism of action 
remains unknown.159 Thus, intensive research has focused on the question whether genetic 
risk variants, either as single variants or combined as genetic risk scores (GRS), can 
supplement clinical risk-prediction tools and help to predict an individual’s risk for CAD 
and ACS more precisely.1,19,21,28,83,104,112,139,180,227,231,242 Even though not used in clinical 
practice, GRSs have shown capability to predict CAD in healthy subjects. The role of 
GRSs in predicting recurrent ACS remains, however, unclear.  
The ACS can be classified into ST-elevation myocardial infarction (STEMI), non-ST-
elevation myocardial infarction (NSTEMI) and unstable angina pectoris (UAP). Patients 
with STEMI usually have fewer clinical risk factors, milder atherosclerosis observed in 
the coronary angiogram, and they are younger than are patients with NSTEMI.127 
Differences occur in the pathophysiology between the two conditions, and the acute 
management of these conditions differs substantially. Additionally, patients seem prone to 
either type of myocardial infarction (MI): in patients suffering from recurrent MI, the 
recurrent event is often of the same type as the first.186 This raises the question whether 
differences also exist in the genetic background of these two conditions.  
More risk variants are revealed for CAD than for other CVD subtypes, which can be 
explained by the broad spectrum of the disease phenotypes and a more heterogeneous 
genetic background. Some of the known genetic CAD risk variants also confer a risk for 
other manifestations of atherosclerosis; they are thus pleiotropic. Consequently, each new 
CAD/MI risk variant should be evaluated in relation to other CVD manifestations.107  
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This study aimed to investigate the effects of genetic variants on ACS: ACS subtype 
and prognosis. Additionally, this study describes the characteristics and findings of a 
cohort of consecutive patients who underwent coronary angiography, and evaluates the 
discovered NSTEMI risk variant in terms of pleiotropy.   
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2. Review of the literature 
2.1. Epidemiology of CAD and ACS 
CAD and ACS are leading causes of death in the developed countries, and CAD is the 
most frequent cause of death worldwide. Every year over seven million people die of 
CAD, which is 12.8% of all deaths worldwide.247 In Europe, CAD causes 20% of all 
deaths: 1.8 million annually.158  
In Finland, for CAD and ACS altogether, hospital admissions annually number more 
than 60 000, of which 13 000 are for ACS. The number of patients suffering from ACS 
was decreasing steadily during 1990s, it peaked in 2000-2003, and has then trended 
downward again.219 CAD mortality in Finland has also decreased since the 1970s. The 
most important reasons for the decline are decreases in risk factors, such as dyslipidemia, 
smoking, and hypertension, in addition to development in treatment strategies.236 
The main reason for the substantial decrease in CAD mortality, at least in Finland and 
Norway, during the past decades is considered to be a decreased prevalence of 
dyslipidemia.110,128,236 However, according to the FINRISK Study, after 2007 the 
cholesterol level has risen again, most likely stemming from the public debate around the 
dietary lipids and the benefits of statins.236  
Whereas in older generations men smoked more often than women, in younger 
generations this gender gap seems to be narrowing. While smoking prevalence in younger 
women is increasing in some regions of the world, it is declining in men.109 This change in 
smoking pattern will most likely cause a substantial increase in MI rates in women.218 In 
Finland, however, tobacco smoking in women, after peaking in 2007, has dropped. Still, 
when compared to about 10% in the 1970s, the rate of tobacco smoking had doubled by 
2012. In contrast, the prevalence of smoking in men has declined from about 50% in 1971 
to 27% in 2012.94 
The overall prevalence of hypertension is estimated to be around 30 to 45%.126 With 
antihypertensive drug-use or blood pressure over 140/90 mmHg as the criterion, as many 
as half of all Finnish men and two-fifths of women over age 30 are considered 
hypertensive.103 The mean blood pressure in Finns decreased from 1970 to 2000 in all age 
groups,95 but started to rise again in 2010.111  
Incidence of STEMI has decreased over the last decade, whereas incidence of 
NSTEMI has increased, possibly resulting from changes in the prevalence of and 
improved treatment for the main risk factors. Short-term mortality from STEMI is higher 
than from NSTEMI, but during one to two years of follow-up, the difference in mortality 
rates evens out.135 Patients with NSTEMI are older and have more co-morbidities than do 
patients with STEMI.127 The known factors related to STEMI mortality include age, Killip 
class,100 time-delay to treatment, mode of treatment, history of prior MI, diabetes mellitus, 
renal insufficiency, severity of CAD disease in angiography, ejection fraction, and 
treatment. 127 
 
 
 
 
15 
2.2. Classification and diagnosis of stable CAD and ACS 
In CAD, oxygen supply to the myocardial cells is diminished due to obstruction of the 
coronary arteries. The resultant imbalance in oxygen supply and demand leads to clinical 
symptoms. In stable CAD, this imbalance is reversible, and is usually caused by a 
combination of narrowed coronary arteries and increased oxygen demand in situations like 
exercise. After the exercise ceases, oxygen demand returns to normal, and the symptoms 
ease.145 In ACS, including MI and UAP, the imbalance is due to the sudden obstruction of 
a coronary artery, and in MI this imbalance leads to myocardial damage due to prolonged 
ischemia.184,207   
Ischemia causes typical symptoms: acute chest pain, possibly radiating to the lower 
jaw and left arm, epigastric discomfort, dyspnea, and fatigue.145 Whereas in stable CAD 
these symptoms are reversible, in ACS the symptoms are worse and typically last more 
than 20 minutes. The ischemia may, however, also be silent or atypical, including diffuse 
discomfort, nausea, palpitations, or cardiac arrest. Women, the elderly, patients with 
diabetes, and critically ill patients are particularly prone to these atypical 
manifestations.226  
Diagnosis of both stable CAD and ACS is based on patient history, symptoms typical 
for ischemia, risk-profiling, physical examination and an electrocardiogram 
(ECG).145,184,207 Myocardial ischemia causes injury currents: alterations in the 
repolarization and depolarization of cardiomyocytes detectable as changes in the 
ECG.43,191 The diagnostics is typically supplemented with exercise ECG testing in stable 
CAD, because ECG changes are reversible and may usually be detectable only during 
exercise.55 In ACS, measurement of cardiac biomarkers is crucial for diagnostics. 
The Multinational Monitoring of Trends and Determinants in Cardiovascular Disease 
(MONICA) Project, coordinated by World Health Organization (WHO), defined uniform 
criteria for MI in the 1980s. These criteria for a definite MI included typical chest pain 
symptoms and either ECG susceptible for ischemia, including the development of Q-
waves, or cardiac biomarker value double the value of the normal upper limit.248,249 At that 
time, the cardiac biomarkers used were aspartate aminotransferase (ASAT), lactate 
dehydrogenase, and creatinine kinase (CK) and its MB isoenzyme. These biomarkers, 
however, may also rise for many reasons other than MI, and to include only definite MIs, 
the cut-off value was defined as considerably high. When the sensitivity and specificity of 
biomarkers developed, and the ability to identify MI improved, the criteria for MI were 
redefined in 2000.6 In the 2000 definition, the ACS were classified at presentation by the 
presence of ST-elevation, and further by evolving ECG changes confirming the 
myocardial necrosis and release of cardiac biomarkers to UAP, non-Q-wave MI and Q-
wave MI. In 2007, the definition was updated and supplemented with a classification of 
the underlying reasons for MI.226 The most recent update of the definition was made in 
2012, with a revised definition of myocardial necrosis and reduced emphasis on 
biomarkers other than cardiac troponin.225 According to this latest definition of MI, the 
crucial criterion for MI is detection of a rise/fall in cardiac biomarkers with at least one 
value above the 99th percentile upper reference limit, accompanied by at least one of the 
following criteria: symptoms of ischemia, new ST-segment/T-wave changes or left bundle 
branch block, development of Q-waves, new loss of viable myocardium or regional 
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motion abnormality, or identification of intracoronary thrombus by angiography or 
autopsy.225   
Figure 1 Classification of acute coronary syndromes. STEMI indicates ST-elevation 
myocardial infarction; NSTEACS, non-ST-elevation acute coronary syndrome; 
NSTEMI, non-ST-elevation myocardial infarction; LBBB, left bundle branch block. 
Reprinted from The Lancet, Volume 372, Issue 9638, 16–22 August 2008, White et al. 
Acute myocardial infarction.  Pages 570–584.90 Copyright (2008), with permission 
from Elsevier.246  
Figure 1 presents the classification of ACS. At presentation, the ACS can be classified 
into three categories: STEMI, non-ST-elevation ACS (NSTEACS) and aborted MI. This 
categorization is essential due to differing treatment approaches and protocols between the 
conditions.184 STEMI generally reflects a total coronary occlusion. The ECG criteria for 
STEMI are persistent ST-segment elevation in at least two contiguous leads or a new left 
bundle branch block.207 In NSTEACS, although transient ST-segment elevation, ST-
segment depression, T-wave inversions or flat T-waves may be present, no persistent ST-
elevation is detectable. The ECG can also be normal.184 NSTEACS is further classified 
into NSTEMI if cardiac biomarkers, indicating myocardial damage, are released, and is 
called unstable angina UAP if biomarker release is undetectable.  
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Figure 2 Time course of the appearance of various markers in the blood after acute 
myocardial infarction (AMI). Shown are the time concentrations/activity curves for 
myoglobin and creatine kinase (CK) isoforms, troponin after large and small 
infarctions, and CK-MB. Note that with cardiac troponin some patients have a second 
peak in addition. CV = coefficient of variation. Reprinted from Journal of the 
American College of Cardiology, Volume 48, Issue 1, 4 July 2006, Jaffe et al. 
Biomarkers in Acute Cardiac Disease: The Present and the Future. Pages 1–11.90 
Copyright (2006), with permission from Elsevier. 
The release of cardiac biomarkers into the blood flow indicates myocardial damage 
due to prolonged ischemia. Today, the most often used cardiac biomarkers are cardiac 
troponin T and I (TnT, TnI), and creatine kinase-MB-mass (CKMBm). These biomarkers 
stay in the blood flow different times (Figure 2). After the introduction of high-sensitivity 
cardiac troponin assays, the number of patients with UAP has dropped and the number of 
patients with NSTEMI has risen accordingly. This change arises from the fact that many 
patients earlier  considered to have UAP due to negative troponin are now diagnosed with 
NSTEMI, because today even a minor release of troponin is detectable.23 Patients with 
UAP do not suffer from myocardial necrosis and thus benefit less than do NSTEMI 
patients from early invasive strategy and intensive antiplatelet therapy.23,152,174 In Helsinki 
University Hospital, the use of high-sensitive-troponin began in 2011.  
Depending on the causes of ischemia and prognostic differences, MI can be classified 
into five types (Table 1).225,226,246 Type 1 is spontaneous MI. It is related to the rupture, 
ulceration, erosion or fissuring of the atherosclerotic plaque, leading to thrombosis, rapid 
occlusion of a coronary artery and thus to myocardial ischemia and necrosis. These 
patients may have severe CAD, but angiography shows that some patients have a non-
obstructive CAD or no CAD at all.24,177,183 In type 2 MI, the ischemia is secondary and 
caused by an imbalance in oxygen supply and demand on the myocardium by conditions 
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other than CAD, such as endothelial dysfunction, coronary artery spasm, embolisms, 
arrhythmias, anemia, respiratory failure, or hypotension or hypertension.225 Type 3 MI is 
cardiac death with preceding symptoms and ECG typical of ischemia, before cardiac 
biomarkers were available. Type 4 and 5 MI are associated with preceding 
revascularization procedures, i.e. PCI and coronary artery by-pass grafting (CABG).225 
 
Table 1. Classification of myocardial infarction by the underlying reason.  
Type Description 
1 Spontaneous myocardial infarction 
2 Infarction secondary to other conditions causing imbalance in oxygen 
supply and demand 
3 Cardiac death with preceding symptoms and ECG typical for ischemia 
4a, 4b, 4c Infarction related to a) percutaneous coronary intervention, b) stent 
thrombosis, or c) restenosis 
5 Infarction related to coronary artery by-pass grafting 
ECG indicates electrocardiogram. Data obtained from Thygesen et al. 225 
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2.3. Pathophysiology  
2.3.1. Formation and composition of an atherosclerotic plaque 
CAD is a multifactorial disease, developing in combination with hyperlipidemia, 
especially involving increased serum concentration of low-density lipoproteins (LDL), 
and other risk factors such as smoking, hypertension, diabetes mellitus, male sex, and 
family history. In a typical patient with advanced CAD numerous plaques of different 
phases are present at different sites in the coronary arterial tree.16 To induce the disease 
requires higher LDL levels than to sustain progression once lesions have formed.16,68  
The process of plaque formation begins with adaptive intimal thickening in response to 
mechanical stress affecting especially the vessel’s inner curvatures and branch points. This 
process begins spontaneously in early childhood. Mechanical stress leads to changes in 
endothelial metabolism and gene expression.244 Pathological intimal thickening is already 
observable in the coronaries at age 20 to 30. Over time, the arterial wall remodels, and 
plaque develops, which changes the local flow patterns.16  
LDLs accumulate in the thickened intima, aggregate, and oxidize. The modified LDLs 
stimulate the immune process and induce, for example, differentiation of monocytes into 
several phenotypes of macrophages and dendritic cells.118 In turn, the immune cells further 
promote the development of lesions and inflammation.16 Macrophages and dendritic cells, 
after their up-take of LDL, become foam cells and lipid deposits. Foam cells layer within 
the proteoglycan of the intima and form fatty streaks, also called as intimal xanthomas, 
which can still be reversible.16 However, if lipid-rich material still keeps accumulating in 
the intima, fatty streaks further develop into progressive atherosclerotic lesions.205  
When the macrophage invasion and the resultant growth of lipid pools form a necrotic 
core, the plaque becomes a fibroatheroma. The necrotic core contains apoptotic remnants 
of cells. In a late necrotic core, no matrix is left, and the changes are irreversible.101 Men 
and women develop the same amount of fatty streaks early in life, but by the age of 30, 
men have developed more progressive atherosclerotic lesions.134 Leaky neovessels grow 
into the base of atherosclerotic lesions. These neovessels are fragile and have few 
supporting cells, and thus they allow the intraplaque bleeding common in fibroatheromas. 
Neovascularization and intraplaque bleeding expand the necrotic core and promote 
inflammation.203 Extravasation can also happen through a ruptured fibrous cap that 
remains between the necrotic core and the vessel lumen.  
Progressive atherosclerotic lesions can be calcified to varying extents. Calcification 
increases with age and can constitute most of the plaque volume. The necrotic core can 
completely calcify. Some plaques can even consist of fibrous and calcified tissue only, 
without any necrotic core or extracellular lipids.204  
 At the time of atherosclerotic plaque development, the local vessel segment is also 
remodeled. This remodeling can be expansive, i.e. the lumen area is usually not reduced 
until plaques become very large. The remodeling can also be constrictive, which leads to 
shrinkage of the vessel segment and the lumen. Expansive remodeling is present in 
fibroatheromas and constrictive remodeling in more fibrous lesions. The mode and extent 
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of remodeling is crucial in determining the severity of the stenosis. Due to remodeling, it 
is impossible to exclude the presence of atherosclerotic plaques by invasive 
angiography.27 
2.3.2. Pathophysiology of ACS 
Sudden obstruction of a coronary artery results in impaired blood flow to those parts of the 
myocardium that the vessel segment supplies. This leads to an inadequate supply of 
oxygen and results in ischemia. The ischemia causes the typical symptoms and ECG 
changes, whereas the plaque disruption itself is symptomless.16 The ischemia may lead to 
myocardial necrosis, causing the release of cardiac biomarkers such as troponin. 
Atherosclerosis alone can cause symptoms of stable angina pectoris, but ACS almost 
always results from a luminal thrombus or a plaque hemorrhage.37,176,228  
The cause of coronary thrombosis is usually a plaque rupture (Figure 3). Rupture of a 
fibrous cap exposes the thrombogenic core to the blood stream. Plaque rupture plays a key 
role in thrombi that cause MI both in patients who survive and in those who die.117 
Smoking is known to predispose every type of coronary plaques to thrombosis. Plaque 
ruptures occur more in patients with STEMI than with NSTEMI.117 
Ruptures are likely in plaques with a thin fibrous cap and a large necrotic core 
infiltrated with macrophages.10 In eccentric plaques, the weakest spots are the cap margins 
and shoulder region. Infiltrating macrophages degrade the cap matrix, and smooth muscle 
cells (SMC) leave the cap, which leads to thinning of the fibrous cap.117 Intraplaque 
macrophages overproduce matrix-metalloproteinases, which have interstitial collagenase 
activity and thus catalyze the attack on fibrillar collagen.200 It remains unclear how long 
the fibrous cap thinning takes, but this is assumed to be a slow process of years or 
decades. Rupturing of a fibrous cap can happen spontaneously, but physical or mental 
stress or activation of the sympathetic nervous system can be the trigger for rupture.16  
Other features associated with plaque vulnerability and rupture are spotty calcification, 
adventitial and perivascular inflammation, neovascularization from the vasa vasorum and 
plaque hemorrhage, and expansive remodeling. Many angiographic studies indicate that 
lesions causing ACS actually are often non-occlusive.117,228 Studies by computed coronary 
tomography angiogram (CCTA) and intraluminal ultrasound have shown that plaques 
associated with ACS include outward expansion of the artery wall and only some 
calcification, and they lie proximal to the sites of maximal stenosis.150,196 
Erosion of plaques can lead to thrombosis. Such eroded plaques are more often 
calcified, less inflamed, and are more often associated with constrictive remodeling than 
are the ruptured plaques. Plaque erosion is a weaker thrombogenic stimulus than is a 
rupture. Plaque erosion occurs more frequently in women than in men, with  
hypertriglyceridemia in particular being linked to erosion.117  
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Figure 3 The pathogenesis of acute coronary syndrome. Ruptures (1) and erosions (2) of the 
atherosclerotic plaques lead to acute coronary syndromes. Ruptures are common in 
plaques with a thin fibrous cap and a large necrotic core (1). Because of expansive 
remodeling, these kinds of plaques are often non-occlusive. Rupture of the plaque 
leads to thrombosis and sudden total occlusion of the coronary artery. Plaques 
associated with erosion are more often calcified and associated with constrictive 
remodeling (2). Erosion is a weaker thrombogenic stimulus than rupture.16  
 
In patients suffering from CAD, many healed ruptures are often present in the coronary 
artery tree. The number of ruptures correlates with the severity of stenosis. Silent erosion, 
rupturing, and healing are important for plaque growth and further stenosis. Negative 
remodeling is often related to severe stenosis.16   
Local inflammation seems to play a key role in plaque disruption, and the systemic 
inflammatory response to MI can worsen the inflammation in all of the plaques, as well. 
This explains why recurrent thrombotic events happen soon after ACS and involve lesions 
not culprits in the first event. Furthermore, this explains why immediate revascularization 
that limits myocardial injury and consequently also systemic inflammation, reduces 
recurrent events more efficiently than does revascularization occurring later after ACS.117 
Statin treatment also has prevented the first and subsequent ACS in many patient 
categories, even though it has a low impact upon actual degree of stenosis.156 Both statin 
treatment and a lipid-lowering diet reduce the content of lipids and inflammatory cells and 
increase the fibrous nature of plaque, thus most likely stabilizing plaques.4,146,214 
Small pre-existing but not working connections between the main coronary arteries, 
i.e. collaterals, may be present, although in coronary angiography they may be invisible. 
They develop slowly, and when a pressure gradient develops as the native coronary artery 
occludes, they open.194 Both chronic ischemia and slow narrowing of the coronary arteries 
stimulate growth in the caliber of the collaterals. Collateral function is positively 
associated with CAD severity.199 In chronic total obstruction of a coronary artery, the 
blood flow though the collaterals prevents severe ischemia and myocardial 
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necrosis.33,199,245 Collateral development may be one of the reasons why older patients 
with excessive atherosclerosis suffer relatively more often from NSTEMI than from 
STEMI.  
2.4. Clinical risk factors of atherosclerosis and ACS 
Because CAD has proven a leading cause of death and demanded considerable health care 
resources for decades, the search for risk factors for the condition has also been extensive. 
The Framingham Study, the landmark study of the CAD risk factors starting back in 1948, 
carefully monitored more than 5 000 individuals and identified physical inactivity, high 
blood pressure, diabetes, blood-lipid profile, and cigarette smoking as major CAD risk 
factors.125 In the 1980s, The Framingham Study and other studies had already suggested 
more than 200 risk factors.80 CAD prevalence increases with age. Male gender is a well-
known risk factor for CAD and MI. Although the percentage of total deaths from CAD 
between genders is approximately the same, premature death before age 65 and 75 is more 
common in males.158  
A crucial risk factor for CAD and MI is dyslipidemia. LDL is a key contributor to 
CAD development. If LDL level is low, clinically relevant CAD cannot develop, 
regardless of other risk factors.208 The risk factors each act differently in atherosclerosis 
development and thus link slightly differently to CVD presentations.  For example, 
smoking predisposes more to MI than to stable CAD,22 hypertension especially to 
stroke,151 and smoking and diabetes mellitus to PAD.54 Moreover, LDL level elevates the 
risk for CAD more than for PAD and stroke.54,253 For example, in patients with familial 
hypercholesterolemia, the risk for fatal stroke does not seem to be as increased as the risk 
for CAD.84 
High serum levels of LDL raise LDL accumulation in the arterial intima. In addition, 
LDL is linked to the inflammation associated with vulnerable plaques. Regardless of the 
method by which LDL is lowered, the risk for MI is reduced.26,118 In contrast to LDL, 
HDL removes lipid particles from the arterial wall. It also acts as an antioxidant and has 
anti-inflammatory properties. However, the interventions to raise HDL level have proven 
of no clinical benefit.118,240 In addition to LDL and HDL cholesterol, triglyceride level is 
also associated with CAD, but it has not been confirmed as a causal risk factor. The level 
of triglycerides is highly associated with other CAD risk factors such as diabetes mellitus, 
but when adjusted for other risk factors, triglycerides have not been associated with 
CAD.118   
Tobacco smoking is associated with an increased risk for acute MI, and is even one of 
the largest contributors to MI worldwide. Smoking promotes atherosclerosis by causing 
endothelial dysfunction, oxidation of proatherogenic lipids, decrease in HDL and 
induction of inflammation.142 Smoking is additionally linked to coronary thrombosis.12,26 
When compared to never-smokers, smokers have a three-fold risk for MI.218 This risk is 
greater in the young than in the old, and correlates with the amount of tobacco used, but 
even low tobacco consumption associates with an elevated MI risk. After smoking 
cessation, the risk starts to decrease over time, but remains higher than in non-smokers.218 
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Women tend to be even more sensitive to tobacco. Smoking women have an up to 25% 
higher risk for CAD than do smoking men.85  
Hypertension not only enhances the CAD development, but also adds to the workload 
of the heart, thus causing an increased oxygen demand in cardiomyocytes. Over the long 
run, hypertension can cause heart failure.46 Hypertension eventually reduces arterial 
elasticity and promotes atherosclerotic plaque formation. A link between inflammation, 
hypertension, and atherosclerosis is angiotensin-II, which, besides its action as a 
vasoconstrictor, is also an initiator of intimal inflammation. It increases expression of 
proinflammatory cytokines on endothelial cells.119 Along with elevated blood pressure, 
CAD risk increases without any threshold value. It has been estimated that each blood-
pressure increase with 20/10 mmHg at least doubles CAD mortality.116 Systolic blood 
pressure and pulse pressure increase slowly with age.57  
Diabetes mellitus is a major contributor to CAD development. It includes a range of 
conditions, the two most common being juvenile-onset diabetes (type 1) and adult-onset 
diabetes (type 2). Most diabetics are of type 2, which often appears together with other 
CAD risk factors as well. Type 2 diabetes is characterized by impaired glucose tolerance, 
which results from development of insulin resistance. The glycosylated hemoglobin 
percentage, reflecting high blood-glucose values, has been associated with subclinical 
CAD independently of other risk factors even in non-diabetic patients,32 and it slightly 
sharpens CAD-risk prediction.42 Additionally, diabetes promotes oxidative stress, 
contributes to the production of proinflammatory cytocines, and enhances other 
inflammatory pathways in endothelial cells.14 Thus, inflammation serves as a link between 
diabetes and atherosclerosis.119 
Obesity not only elevates risk for CAD and ACS but also the risk for diabetes, 
dyslipidemia, and overall atherosclerosis. Moreover, adipose tissue promotes 
inflammation by synthesizing cytokines.119 Obesity is a major problem all over the world, 
especially in developing countries. For approximating ACS risk, waist-to-hip and waist-
to-height ratios are considered more useful than body-mass index (BMI).195,261 In 
metabolic syndrome, the main risk factors, except for smoking, are all linked.  Insulin 
resistance, hyperglycemia, hyperleptinemia, hypertension, and dyslipidemia, all present in 
metabolic syndrome, enhance atherosclerosis by differing mechanisms.209  
Inflammation links the main risk factors and marks atherosclerosis development. 
Inflammatory cells in atherosclerotic lesions secrete proinflammatory cytokines, which 
induce hepatic C-reactive protein (CRP) production. In some studies, elevated CRP has 
predicted cardiovascular risk even better than does LDL level. CRP also correlates with 
CAD severity.178,179 
Risk factors for CAD probably vary between populations, with lipids not being 
associated with CAD in south Asians, in the Chinese and in the Japanese, where high 
blood pressure may, in turn, play a larger role.263 Moreover, prevalence of these risk 
factors varies among populations. The INTERHEART Study, a large multicenter cohort 
purposed to study CAD risk factors in different populations, evaluated nine easily 
measured, potentially modifiable risk factors to account for as much as 90% of the risk for 
the first MI. This effect is consistent in men and women, and across geographic regions 
and ethnic groups.262 The INTERHEART study defines tobacco smoking and an abnormal 
blood lipid profile as the most important risk factors, other factors accounting for the risk 
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being diabetes, hypertension, abdominal obesity, psychosocial factors, and lifestyle factors 
including low fruit and vegetable intake, physical inactivity and alcohol use. 
Women suffering from any type of ACS are older, and more likely to be hypertensive 
and diabetic than are their male counterparts. Instead, men with ACS are more likely to be 
smokers.5,7,75 Several studies of coronary angiography patients demonstrate that men tend 
to have angiographically more severe CAD than do women.17,41,105 Age and presence of 
traditional risk factors correlates positively with the number of diseased coronary arteries, 
but these have no effect before age 65.241 
2.5. Treatment of stable CAD and ACS 
Treatment of stable CAD includes treating all diagnosed risk factors and preventing any 
that the patient does not yet have by means of lifestyle changes and correctly chosen 
medication.  The aim of the treatment is to improve quality of life by easing symptoms, to 
prevent ACS, and to improve prognosis. If the patient suffers from difficult symptoms 
regardless of adequate medical therapy, revascularization by PCI or CABG can be 
considered.145 Statin therapy improves the prognosis of CAD patients, and should 
therefore be prescribed for every CAD patient regardless of LDL level, in the absence of 
contraindications.86,157,165 The goal of the lipid treatment is an LDL level under 1.8 
mmol/L. Systolic blood pressure should be lowered to 135 mmHg and diastolic to 85 
mmHg. The glycosylated hemoglobin A1c (HbA1c) should be lowered to under 53 
mmol/mol. These goals should be taken into consideration while monitoring a patient with 
stable CAD and in choosing the combination of medications, but each patient’s individual 
characteristics also matter.145  
In ACS patients, the classification to either STEMI or NSTEACS guides the choice of 
acute treatment.184,207 With the exception of antiplatelet treatment, management after the 
ACS is similar to the management of patients with stable CAD. Whereas in STEMI 
patients, an immediate revascularization by medical thrombolysis or PCI is crucial for 
survival, in NSTEACS patients the primary therapy is medical, with coronary angiography 
conducted within a few days after disease onset.11,184 When compared to delayed 
revascularization strategy, revascularization conducted within 12 hours after symptom 
onset has been associated with a higher survival rate and reduction in development of 
large myocardial damage at 30 days.155 However, another study showed no difference 
between these same groups in mortality, MI, or urgent revascularization at 30 days.144  
In addition to the revascularization, intensive antithrombotic therapy is vital to treat 
ACS effectively, including both antiplatelet agents and anticoagulants.18,138 Standard 
treatment in Finland includes acetylsalicylic acid combined with clopidogrel, prasugrel or 
ticagrelor as antiplatelet medication, and low-molecular-weight heparin.210,211  
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2.6. Genetics of CAD 
Besides the traditional risk factors of atherosclerosis, genetics also plays a critical part in 
CAD development. Family history was already identified decades ago as an independent 
risk factor. CAD is a complex disease and heritable in a multifactorial manner, meaning 
the contribution of several genes together with environmental factors.181 Genetic factors 
account for up to 30 to 60% of the variation in the CAD risk.121,130 Even though the 
genetic risk for each individual is predefined, a healthy lifestyle may still prevent actual 
onset of the disease.  
Genome-wide association studies (GWAS) have identified more than 50 loci that 
predispose to the development of CAD or MI. 
9,34,39,40,50,66,71,74,87,96,123,136,159,175,190,198,234,243,257 GWAS compare the allele frequency of 
single nucleotide polymorphisms (SNPs) across the genome between cases and controls in 
study samples including thousands of individuals.197 GWAS preferentially cover common 
SNPs with minor allele frequency (MAF) greater than 5 to 15% to achieve high statistical 
power for detecting associations. Consequently, most of the identified CAD risk alleles 
are quite common. The increasing number of identified risk loci and their high frequency 
in population means that most individuals are likely to carry several CAD risk variants.98 
The genetic risk for CAD is additive, and each risk allele contributes to the risk for a small 
proportion.98  
Instead of being causal, the risk SNPs mark a linkage disequilibrium (LD) block, a 
particular region on a chromosome, in which the actual causal variant is located.98 The 
majority of the risk SNPs locate in noncoding sequences. They exert their effect through 
mediation of nearby protein-coding sequences in the same chromosome and possibly also 
in other chromosomes.181 Therefore, the discovery of a risk SNP leads to a search for the 
actual causal variant and the pathway behind the elevated risk. Some of the risk SNPs are 
suggested to affect expression of the nearby genes in a quantitative way, thus contributing 
to CAD risk.34 Not all SNPs with the strongest effect are located near protein-coding 
regions. Since only a minority of the risk SNPs revealed seems to act via one of the 
traditional risk factors, for most of the risk SNPs, the mechanism remains unknown.181 
Further, in regions with a link discovered between a risk SNP and a specific gene, the 
majority of these genes have not been linked to CAD pathogenesis before. Knowledge of 
the mechanisms behind risk-allele associations is still incomplete.98  
CAD genetics is suspected to be, at least in part, population-specific. Most of the 
GWAS for CAD have been performed in populations of European ancestry. However, a 
GWAS discovered loci related to CAD in Han Chinese.123 These loci have not been linked 
to CAD in European populations, but they are associated with hypertension. A Japanese 
GWAS also found novel susceptibility loci for CAD.74 
2.6.1. Revealed genetic risk variants for CAD 
New risk variants for CAD/MI are emerging increasingly rapidly. The first CAD risk loci 
were discovered in GWAS performed in 2007. Since then, cohort sizes have increased, 
and the imputation methods have improved. The largest international cohorts this far, 
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including the CARDIoGRAMplusC4D Consortium, have discovered or replicated 
altogether more than 50 CAD risk variants (Table 2). Moreover, some variants show 
association with CAD only in specified populations, and some of the variants are awaiting 
replication. In addition to the genome-wide significant risk variants, dozens of suggestive 
variants strongly, but not genome-wide significantly, have been presented.40,159  
The first and best-known locus found to be associated with CAD is 9p21, which was 
found simultaneously but independently by an American136 and an Icelandic71 research 
group. This common locus acts independently of known risk factors. The increased 
relative risk for CAD was 25% for heterozygotes and 50% for homozygotes.181 The 
mechanism behind the risk is unknown, but strong evidence indicates that it is 
proatherogenic and acts at the vessel wall.76,92 The 9p21 variant associates only with CAD, 
not with MI.81 This variant is also associated with progression of CAD judged by the 
number of diseased coronary arteries.28 In another study, this locus, however, was 
unrelated to the incidence of MI and mortality.81  
Besides CAD, few data exist regarding the genetics associating directly with ACS or 
specifically with either STEMI or NSTEMI.182 However, the variants affecting risk for 
ACS differ from those affecting atherosclerosis development; the former may instead 
contribute to thrombosis, plaque rupture, or release of tissue-coagulation factors.181 Thus 
far, only the ABO blood group locus at 9q34.2 has shown an association with MI.175,189 In 
a 20-year follow-up study, the A and B risk variants were associated with a 10% increased 
frequency of MI, and a combination of A and B elevated this risk to 20%.69  
A locus at 1p13.3 is known to associate with diminished risk for both CAD and MI, 
acting in part through lower LDL levels.96,153,251 In one study, this locus was associated 
with reduced risk of readmission for NSTEMI and a lower CVD readmission rate, 
independent of established predictors of increased risk.49  
Chromosome 1q41 has been associated with CAD and MI in multiple GWAS. It 
elevates CAD risk by 14%.50,96,189,190 In a study of three different cohorts, an independent 
association existed between the variant at 1q41 and survival/readmission. When compared 
with CC carriers, significantly fewer healthy participants carrying AC/CC experienced an 
NSTEMI throughout their follow-up. 49 
Risk factors are also under genetic regulation. Already more than 150 genetic risk 
variants are known to associate with blood lipid levels.220,252 An accumulation of genetic 
risk variants can make patients unresponsive to treatment of their blood lipid levels. 
Additionally, multiple risk variants associated with hypertension and diabetes mellitus 
have emerged.48,147,193 
 
    
27 
Ta
bl
e 
2.
 
C
or
on
ar
y 
ar
te
ry
 d
is
ea
se
 a
nd
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n 
ri
sk
 v
ar
ia
nt
s a
nd
 th
ei
r u
se
 in
 ri
sk
 p
re
di
ct
io
n 
m
od
el
s. 
 
 
G
en
es
 in
vo
lv
ed
 
Y
ea
r 
O
ri
gi
na
l 
re
fe
re
nc
e(
s)
 
Fu
nc
tio
n 
an
d 
po
ss
ib
le
 
re
le
va
nc
e 
to
 C
A
D
 
L
ea
d 
SN
P 
an
d 
pr
ox
y 
SN
Ps
 
In
cl
ud
ed
 in
 r
is
k 
sc
or
es
 
M
in
or
/ 
m
aj
or
 a
lle
le
 
1p
13
 
SO
R
T1
 
20
07
 
Sa
m
an
i19
0  
LD
L 
ch
ol
es
te
ro
l18
1  
rs
59
98
39
 
Tr
ag
an
te
,23
1  K
ra
ru
p,
10
4  B
jo
rn
ss
on
,19
 
B
ol
to
n2
1  
A
/G
 
 
 
 
 
 
rs
64
67
76
 
La
bo
s,1
12
 M
eg
a,
13
9  H
ug
he
s,8
3  
Ti
kk
an
en
,22
7  R
ip
at
ti1
80
 
T/
C
 
1q
21
  
IL
6R
 
20
13
 
D
el
ou
ka
s4
0  
Im
m
un
e 
re
sp
on
se
13
7  
rs
48
45
62
5 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
T/
C
 
1p
32
 
PP
A
P2
B
 
20
11
 
Sc
hu
nk
er
t19
8  
R
eg
ul
at
io
n 
of
 c
el
l-c
el
l 
in
te
ra
ct
io
ns
13
7  
rs
17
11
40
36
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  B
ol
to
n2
1  
A
/G
 
1q
41
 
M
IA
3 
20
07
 
Sa
m
an
i19
0  
C
ol
la
ge
n 
se
cr
et
io
n1
37
 
rs
17
46
56
37
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  R
ip
at
ti,
18
0  
B
ol
to
n2
1  
C
/A
 
 
 
 
 
 
rs
17
46
48
57
 
K
ra
ru
p1
04
 
C
/T
 
 
 
 
 
 
rs
17
01
16
66
 
B
ol
to
n2
1  
G
/A
 
 
 
 
 
 
rs
21
33
18
9 
 
T/
C
 
 
 
 
 
 
rs
30
08
62
1 
H
ug
he
s8
3  
A
/G
 
1p
32
 
PC
SK
9-
B
SN
D
 
20
09
 
K
at
hi
re
sa
n9
6   
LD
L 
ch
ol
es
te
ro
l18
1  
rs
11
20
65
10
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
H
ug
he
s,8
3  B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  
R
ip
at
ti,
18
0  B
ol
to
n2
1  
T/
C
 
2p
11
 
V
A
M
P5
-
V
A
M
P8
-G
G
C
X
 
20
13
 
D
el
ou
ka
s4
0  
In
tra
ce
llu
la
r v
es
ic
le
 
tra
ff
ic
13
7  
rs
15
61
19
8 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
A
/G
 
2p
21
 
A
B
C
G
5-
A
B
C
G
8 
20
11
 
IB
C
 5
0K
 C
A
D
 
C
on
so
rti
um
87
  
LD
L 
ch
ol
es
te
ro
l18
1  
rs
65
44
71
3 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
T/
C
 
 
 
 
 
 
rs
42
99
37
6 
 
 
2p
24
 
A
PO
B
 
20
13
 
D
el
ou
ka
s4
0  
LD
L 
ch
ol
es
te
ro
l18
1  
rs
51
51
35
 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
G
/A
 
    
28 
 
G
en
es
 in
vo
lv
ed
 
Y
ea
r 
O
ri
gi
na
l 
re
fe
re
nc
e(
s)
 
Fu
nc
tio
n 
an
d 
po
ss
ib
le
 
re
le
va
nc
e 
to
 C
A
D
 
L
ea
d 
SN
P 
an
d 
pr
ox
y 
SN
Ps
 
In
cl
ud
ed
 in
 r
is
k 
sc
or
es
 
M
in
or
/ 
m
aj
or
 a
lle
le
 
2p
24
 
TT
C
32
-
W
D
R
35
* 
20
12
 
Lu
12
3  
 
rs
21
23
53
6 
 
A
/G
 
2q
33
 
W
D
R
12
 
20
09
 
K
at
hi
re
sa
n9
6   
C
om
po
ne
nt
 o
f n
uc
le
ar
 
pr
ot
ei
n 
co
m
pl
ex
13
7  
rs
67
25
88
7 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
H
ug
he
s,8
3  B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  
R
ip
at
ti,
18
0  B
ol
to
n2
1  
C
/T
 
2q
36
 
Ps
eu
do
ge
ne
 
EN
SG
00
00
00
19
72
18
 
20
07
 
Sa
m
an
i19
0  
 
rs
29
43
63
4 
 
A
/C
 
2p
24
 
A
K
09
79
27
 
20
13
 
D
el
ou
ka
s4
0  
 
rs
16
98
69
53
 
 
A
/G
 
2q
22
 
ZE
B
2-
A
C
O
74
09
3.
1 
20
13
 
D
el
ou
ka
s4
0  
ZE
B
2 
tra
ns
cr
ip
tio
na
l 
re
pr
es
so
r1
37
 
rs
22
52
64
1 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
G
/A
 
3q
22
 
M
R
A
S 
 
20
09
 
Er
dm
an
n5
0  
C
el
l g
ro
w
th
 a
nd
 
di
ffe
re
nt
ia
tio
n1
37
 
rs
98
18
87
0 
La
bo
s,1
12
 K
ra
ru
p,
10
4  M
eg
a,
13
9  H
ug
he
s,8
3  
B
jo
rn
ss
on
,19
 R
ip
at
ti1
80
 
T/
C
 
 
 
 
 
 
rs
23
06
37
4 
Tr
ag
an
te
,23
1  T
ik
ka
ne
n,
22
7  B
ol
to
n2
1  
C
/T
 
3p
24
 
PL
C
L2
**
 
20
14
 
H
iro
ka
w
a7
4  
In
fla
m
m
at
io
n 
rs
46
18
21
0 
 
G
/A
 
4q
31
 
G
U
C
Y
1A
3 
20
12
 
D
el
ou
ka
s,4
0  
Lu
12
3  
H
yp
er
te
ns
io
n1
81
 
rs
76
92
38
7 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
G
/A
 
 
 
 
 
 
rs
18
42
89
6 
 
G
/T
 
 
 
 
 
 
rs
27
39
09
 
 
G
/A
 
4q
31
 
ED
N
R
A
 
20
13
 
D
el
ou
ka
s4
0  
V
as
oc
on
st
ric
tio
n1
37
 
rs
18
78
40
6 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
T/
C
 
4q
12
 
R
ES
T-
N
O
A
1 
20
15
 
N
ik
pa
y1
59
 
SM
C
s i
n 
a 
qu
ie
sc
en
t 
st
at
e1
37
 
rs
17
08
73
35
 
 
T/
G
 
5p
15
 
IR
X
1 
20
11
 
A
ok
i9  
 
rs
11
74
83
27
 
Tr
ag
an
te
23
1  
C
/T
 
5q
31
 
IL
5?
 
20
11
 
IB
C
 5
0K
 C
A
D
 
C
on
so
rti
um
87
 
 
rs
27
06
39
9 
 
 
G
/T
 
 
 
 
 
 
 
 
 
    
29 
 
G
en
es
 in
vo
lv
ed
 
Y
ea
r 
O
ri
gi
na
l 
re
fe
re
nc
e(
s)
 
Fu
nc
tio
n 
an
d 
po
ss
ib
le
 
re
le
va
nc
e 
to
 C
A
D
 
L
ea
d 
SN
P 
an
d 
pr
ox
y 
SN
Ps
 
In
cl
ud
ed
 in
 r
is
k 
sc
or
es
 
M
in
or
/ 
m
aj
or
 a
lle
le
 
5q
31
 
SL
C
22
A
4-
SL
C
22
A
5 
20
13
 
D
el
ou
ka
s4
0  
O
rg
an
ic
 c
at
io
n 
tra
ns
po
rte
r1
37
 
rs
27
39
09
 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
C
/T
 
 
 
 
 
 
rs
20
48
32
7 
H
ug
he
s8
3  
A
/G
 
6p
21
  
K
C
N
K
5 
20
13
 
D
el
ou
ka
s4
0  
Po
ta
ss
iu
m
 c
ha
nn
el
 
pr
ot
ei
n1
37
 
rs
10
94
77
89
 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
T/
C
 
6p
21
 
A
N
K
S1
A
 
20
11
 
Sc
hu
nk
er
t19
8  
H
D
L 
ch
ol
es
te
ro
l18
1  
rs
17
60
99
40
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n2
27
 
G
/C
 
 
 
 
 
 
rs
12
20
53
31
  
 
T/
C
 
 
 
 
 
 
rs
20
77
75
0 
K
ra
ru
p1
04
 
G
/A
 
6p
21
 
H
C
G
27
-H
LA
-B
- 
H
LA
-C
  
20
12
 
D
av
ie
s3
9  
 
rs
38
69
10
9 
 
 
G
/A
 
6p
21
 
C
6o
rf
10
-
B
TN
L2
* 
20
12
 
Lu
12
3  
 
rs
92
68
40
2 
 
A
/G
 
6p
22
 
B
TN
2A
1*
* 
20
11
 
Y
am
ad
a 
25
7  
 
rs
69
29
84
6 
 
 
T/
C
 
6q
23
 
TC
F2
1 
20
11
 
Sc
hu
nk
er
t19
8   
Tr
an
sc
rip
tio
na
l 
re
gu
la
to
r1
37
 
rs
12
19
02
87
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 B
ol
to
n2
1  
C
/G
 
 
 
 
 
 
rs
19
67
91
7 
 
A
/G
 
6p
24
 
PH
A
C
TR
1 
20
09
 
K
at
hi
re
sa
n9
6   
Pr
ot
ei
n 
ph
os
ph
at
as
e 
1 
ac
tiv
ity
 re
gu
la
tio
n1
37
 
rs
12
52
64
53
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  
H
ug
he
s,8
3  B
jo
rn
ss
on
,19
 T
ik
ka
ne
n2
27
 
C
/G
 
 
 
 
 
 
rs
93
49
37
9 
M
eg
a,
13
9  R
ip
at
ti1
80
 
C
/T
 
 
 
 
 
 
rs
13
32
84
4 
B
ol
to
n2
1  
C
/T
 
6p
24
 
A
D
TR
P-
C
6o
rf
10
5*
 
20
12
 
Lu
12
3  
 
rs
69
03
95
6 
Tr
ag
an
te
23
1  
A
/G
 
6q
25
 
M
TH
FD
1L
 
20
07
 
Sa
m
an
i,1
90
 
W
TC
C
C
24
3   
 
 
rs
69
22
26
9 
 
A
/G
 
6q
25
 
SL
C
22
A
1-
SL
C
22
A
3 
20
09
 
Tr
eg
ou
et
23
4  
Li
po
pr
ot
ei
n(
a)
13
7  
rs
20
48
32
7 
H
ug
he
s,8
3  B
jo
rn
ss
on
19
 
C
/T
 
    
30 
 
G
en
es
 in
vo
lv
ed
 
Y
ea
r 
O
ri
gi
na
l 
re
fe
re
nc
e(
s)
 
Fu
nc
tio
n 
an
d 
po
ss
ib
le
 
re
le
va
nc
e 
to
 C
A
D
 
L
ea
d 
SN
P 
an
d 
pr
ox
y 
SN
Ps
 
In
cl
ud
ed
 in
 r
is
k 
sc
or
es
 
M
in
or
/ 
m
aj
or
 a
lle
le
 
6q
25
 
LP
A
 
20
09
 
Tr
eg
ou
et
23
4  
LD
L 
ch
ol
es
te
ro
l18
1  
rs
37
98
22
0 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  R
ip
at
ti,
18
0  
B
ol
to
n2
1  
C
/T
 
 
 
 
 
 
rs
10
45
58
72
 
M
eg
a,
13
9  B
jo
rn
ss
on
19
 
G
/A
 
 
 
 
 
 
rs
31
27
59
9 
H
ug
he
s8
3   
A
/G
 
 
 
 
 
 
rs
77
67
08
4 
 
H
ug
he
s8
3   
C
/T
 
 
 
 
 
 
rs
10
75
55
78
  
H
ug
he
s8
3   
G
/C
 
6q
26
  
PL
G
 
20
13
 
D
el
ou
ka
s4
0  
Fi
br
in
ol
ys
is
13
7  
rs
42
52
12
0 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
T/
C
 
7p
21
 
H
D
A
C
9 
20
13
 
D
el
ou
ka
s4
0  
R
ep
re
ss
es
 b
ei
ge
 
ad
ip
og
en
es
is
13
7  
rs
20
23
93
8 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
G
/A
 
7q
22
 
7q
22
-B
C
A
P2
9 
20
11
 
C
4D
 G
en
et
ic
s 
C
on
so
rti
um
34
 
 
rs
10
95
35
41
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  B
jo
rn
ss
on
,19
 
Ti
kk
an
en
22
7  
C
/T
 
 
 
 
 
 
rs
12
53
98
95
 
K
ra
ru
p1
04
 
A
/G
 
7q
32
 
ZC
3H
C
1 
20
11
 
Sc
hu
nk
er
t19
8  
En
co
de
s r
eg
ul
at
or
 o
f c
el
l 
pr
ol
ife
ra
tio
n1
37
 
rs
11
55
69
24
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  B
ol
to
n2
1  
C
/T
 
7q
36
 
N
O
S3
 
20
15
 
N
ik
pa
y1
59
 
Pr
od
uc
tio
n 
of
 n
itr
ic
 
ox
id
e,
 h
yp
er
te
ns
io
n1
37
 
rs
39
18
22
6 
 
T/
C
 
8p
22
  
LP
L 
20
13
 
D
el
ou
ka
s4
0  
Li
po
ly
si
s o
f 
lip
op
ro
te
in
s1
37
 
rs
26
4 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
G
/A
 
8q
24
 
TR
IB
1?
 
20
11
 
IB
C
 5
0K
 C
A
D
 
C
on
so
rti
um
87
 
Tr
ig
yc
er
id
es
18
1  
rs
29
54
02
9 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
A
/T
 
 
 
 
 
 
rs
17
32
15
15
 
 
G
/A
 
 
 
 
 
 
rs
10
80
85
46
 
 
A
/G
 
 
 
 
 
 
 
 
 
    
31 
 
G
en
es
 in
vo
lv
ed
 
Y
ea
r 
O
ri
gi
na
l 
re
fe
re
nc
e(
s)
 
Fu
nc
tio
n 
an
d 
po
ss
ib
le
 
re
le
va
nc
e 
to
 C
A
D
 
L
ea
d 
SN
P 
an
d 
pr
ox
y 
SN
Ps
 
In
cl
ud
ed
 in
 r
is
k 
sc
or
es
 
M
in
or
/ 
m
aj
or
 a
lle
le
 
9p
21
 
C
D
K
N
2A
- 
C
D
K
N
2B
 
20
07
 
H
el
ga
do
tti
r,7
1  
M
cP
he
rs
on
13
6  
V
es
se
l w
al
l, 
ce
ll 
pr
ol
ife
ra
tio
n 
an
d 
in
fla
m
m
at
io
n9
2,
13
7  
rs
49
77
57
4 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  M
eg
a,
13
9  
Ti
kk
an
en
,22
7  R
ip
at
ti1
80
 
G
/A
 
 
 
 
 
 
rs
10
75
72
74
 
 
G
/A
 
 
 
 
 
 
rs
23
83
20
6 
 
G
/A
 
 
 
 
 
 
rs
32
17
99
2 
 
T/
C
 
 
 
 
 
 
rs
13
33
04
9 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
,19
 B
ol
to
n,
21
 
H
ug
he
s8
3  
C
/G
 
 
 
 
 
 
rs
10
75
72
78
 
 
G
/A
 
9q
34
 
A
B
O
 
20
11
 
R
ei
lly
17
5   
Th
ro
m
bo
ge
ne
si
s, 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n1
81
 
rs
57
94
59
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  B
ol
to
n2
1  
C
/T
 
 
 
 
 
 
rs
94
11
48
9 
M
eg
a1
39
 
T/
C
 
 
 
 
 
 
rs
65
10
07
 
 
T/
C
 
10
p1
1 
 
K
IA
A
14
62
 
20
11
 
C
4D
 G
en
et
ic
s 
C
on
so
rti
um
34
 
C
om
po
ne
nt
 o
f 
en
do
th
el
ia
l c
el
l-c
el
l 
ju
nc
tio
ns
13
7  
rs
25
05
08
3 
La
bo
s,1
12
 K
ra
ru
p,
10
4  B
jo
rn
ss
on
,19
 
B
ol
to
n2
1  
C
/T
 
 
 
 
 
 
rs
37
39
99
8 
Tr
ag
an
te
23
1  
C
/G
 
10
q1
1 
 
C
X
C
L1
2-
 
H
N
R
N
PA
3P
1 
20
07
 
Sa
m
an
i19
0   
In
fla
m
m
at
io
n,
 
ne
ut
ro
ph
il 
m
ig
ra
tio
n 
13
7  
rs
17
46
04
8 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  M
eg
a,
13
9  
Ti
kk
an
en
,22
7  R
ip
at
ti,
18
0  B
ol
to
n2
1  
C
/T
 
 
 
 
 
 
rs
91
50
83
 
 
A
/C
 
 
 
 
 
 
rs
20
47
00
9 
B
jo
rn
ss
on
19
 
C
/T
 
 
 
 
 
 
rs
50
11
20
 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
,19
 H
ug
he
s8
3  
A
/G
 
 
 
 
 
 
 
 
 
    
32 
 
G
en
es
 in
vo
lv
ed
 
Y
ea
r 
O
ri
gi
na
l 
re
fe
re
nc
e(
s)
 
Fu
nc
tio
n 
an
d 
po
ss
ib
le
 
re
le
va
nc
e 
to
 C
A
D
 
L
ea
d 
SN
P 
an
d 
pr
ox
y 
SN
Ps
 
In
cl
ud
ed
 in
 r
is
k 
sc
or
es
 
M
in
or
/ 
m
aj
or
 a
lle
le
 
10
q2
3 
LI
PA
 
20
11
 
C
4D
 G
en
et
ic
s 
C
on
so
rti
um
,34
 
IB
C
 5
0K
 C
A
D
 
C
on
so
rti
um
87
 
In
tra
ce
llu
la
r h
yd
ro
ly
si
s 
of
 c
ho
le
st
er
ol
 e
st
er
s1
37
 
rs
14
12
44
4 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n2
27
 
T/
C
 
 
 
 
 
 
rs
22
46
94
2 
 
G
/A
 
 
 
 
 
 
rs
11
20
30
42
 
 
T/
C
 
 
 
 
 
 
 
 
 
10
q2
4 
C
Y
P1
7A
1-
C
N
N
M
2-
N
T5
C
2 
20
11
 
Sc
hu
nk
er
t19
8  
St
er
oi
do
ge
ni
c 
pa
th
w
ay
13
7  
rs
12
41
34
09
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  R
ip
at
ti,
18
0  
B
ol
to
n2
1  
G
/A
 
 
 
 
 
 
rs
12
41
18
86
 
 
A
/C
 
11
q2
2 
PD
G
FD
 
20
11
 
C
4D
 G
en
et
ic
s 
C
on
so
rti
um
34
 
Pr
ol
ife
ra
tio
n 
of
 S
M
C
s1
37
  
rs
97
48
19
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  
B
jo
rn
ss
on
,19
 B
ol
to
n2
1  
A
/G
 
11
q2
3 
 
A
PO
A
5-
A
PO
C
3-
ZN
F2
59
 
20
11
 
Sc
hu
nk
er
t19
8  
Tr
ig
ly
ce
rid
es
 
m
et
ab
ol
is
m
13
7,
18
1  
rs
96
41
84
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n2
27
  
G
/A
 
 
 
 
 
 
rs
93
26
24
6 
K
ra
ru
p1
04
 
G
/C
 
11
p1
5 
SW
A
P7
0 
20
15
 
N
ik
pa
y1
59
 
Le
uk
oc
yt
e 
an
d 
SM
C
 
m
ig
ra
tio
n 
an
d 
ad
he
si
on
13
7  
rs
10
84
02
93
 
 
A
/G
 
12
q2
4 
 
SH
2B
3 
20
09
 
G
ud
bj
ar
ts
so
n6
6   
N
eg
at
iv
e 
re
gu
la
to
r o
f 
cy
to
ki
ne
 si
gn
al
in
g,
13
7  
hy
pe
rte
ns
io
n1
81
 
rs
31
84
50
4 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  R
ip
at
ti,
18
0  
B
ol
to
n,
21
 H
ug
he
s8
3  
T/
C
 
 
 
 
 
 
rs
65
31
78
 
 
G
/T
 
12
q2
4 
H
N
F1
A
 
20
09
 
Er
dm
an
n5
0  
 
rs
22
59
81
6 
La
bo
s,1
12
 M
eg
a,
13
9  T
ik
ka
ne
n,
22
7  R
ip
at
ti1
80
 
G
/T
 
 
 
 
 
 
rs
11
69
31
3 
 
C
/T
 
12
q2
1 
 
A
TP
2B
1*
 
20
12
 
Lu
12
3  
In
tra
ce
llu
la
r c
al
ci
um
 
ho
m
eo
st
as
is
13
7  
rs
71
36
25
9 
 
T/
C
 
    
33 
 
G
en
es
 in
vo
lv
ed
 
Y
ea
r 
O
ri
gi
na
l 
re
fe
re
nc
e(
s)
 
Fu
nc
tio
n 
an
d 
po
ss
ib
le
 
re
le
va
nc
e 
to
 C
A
D
 
L
ea
d 
SN
P 
an
d 
pr
ox
y 
SN
Ps
 
In
cl
ud
ed
 in
 r
is
k 
sc
or
es
 
M
in
or
/ 
m
aj
or
 a
lle
le
 
12
q2
4 
K
SR
2 
20
15
 
N
ik
pa
y1
59
 
O
be
si
ty
13
7  
rs
11
83
01
57
 
 
G
/T
 
13
q1
2 
 
FL
T1
 
20
13
 
D
el
ou
ka
s4
0  
A
ng
io
ge
ne
si
s1
37
 
rs
93
19
42
8 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
A
/G
 
13
q3
4 
 
C
O
L4
A
1-
A
2 
20
11
 
Sc
hu
nk
er
t19
8  
Ty
pe
 IV
 c
ol
la
ge
n 
ch
ai
n 
of
 b
as
em
en
t 
m
em
br
an
e1
37
 
rs
47
73
14
4 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  B
ol
to
n2
1  
G
/A
 
 
 
 
 
 
rs
95
15
20
3 
B
jo
rn
ss
on
19
 
T/
C
 
 
 
 
 
 
rs
38
09
34
6 
 
C
/T
 
14
q3
2 
H
H
IP
L1
 
20
11
 
Sc
hu
nk
er
t19
8  
 
rs
28
95
81
1 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  B
ol
to
n2
1  
C
/T
 
15
q2
5 
A
D
A
M
TS
7 
20
11
 
C
4D
 
C
on
so
rti
um
,34
 
R
ei
lly
,17
5  
Sc
hu
nk
er
t19
8  
Pr
ol
ife
ra
tiv
e 
re
sp
on
se
 to
 
va
sc
ul
ar
 in
ju
ry
13
7  
rs
38
25
80
7 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n2
27
 
A
/G
 
 
 
 
 
 
rs
71
73
74
3 
K
ra
ru
p1
04
 
T/
C
 
 
 
 
 
 
rs
43
80
02
8 
Ti
kk
an
en
,22
7  B
ol
to
n2
1  
C
/T
 
15
q2
6 
FU
R
IN
-F
ES
 
20
13
 
D
el
ou
ka
s4
0  
H
yp
er
te
ns
io
n1
81
 
rs
17
51
48
46
 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
A
/C
 
15
q2
2 
SM
A
D
3 
20
07
 
Sa
m
an
i19
0  
M
ed
ia
to
r o
f 
tra
ns
fo
rm
in
g 
gr
ow
th
 
fa
ct
or
-β
 si
gn
al
in
g1
37
 
rs
17
22
82
12
 
 
C
/T
 
 
 
 
 
 
rs
56
06
21
35
 
 
C
/T
 
15
q2
6 
M
FG
E8
-
A
B
H
D
2 
20
15
 
N
ik
pa
y1
59
 
N
eo
va
sc
ul
ar
iz
at
io
n1
37
 
rs
80
42
27
1 
 
G
/A
 
17
p1
1 
R
A
I1
-P
EM
T-
R
A
SD
1 
20
11
 
Sc
hu
nk
er
t19
8  
 
rs
12
93
65
87
 
La
bo
s,1
12
 K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  B
ol
to
n2
1  
G
/A
 
17
p1
3 
SM
G
6-
SR
R
 
20
11
 
Sc
hu
nk
er
t19
8  
 
rs
21
61
72
 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n2
27
 
C
/G
 
 
 
 
 
 
rs
14
34
99
 
K
ra
ru
p1
04
 
C
/T
 
    
34 
 
G
en
es
 in
vo
lv
ed
 
Y
ea
r 
O
ri
gi
na
l 
re
fe
re
nc
e(
s)
 
Fu
nc
tio
n 
an
d 
po
ss
ib
le
 
re
le
va
nc
e 
to
 C
A
D
 
L
ea
d 
SN
P 
an
d 
pr
ox
y 
SN
Ps
 
In
cl
ud
ed
 in
 r
is
k 
sc
or
es
 
M
in
or
/ 
m
aj
or
 a
lle
le
 
17
q2
1 
U
B
E2
Z-
G
IP
 
20
11
 
Sc
hu
nk
er
t19
8  
A
po
pt
os
is
13
7  
rs
46
52
2 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
19
 
T/
C
 
 
 
 
 
 
rs
15
56
3 
K
ra
ru
p1
04
 
C
/T
 
17
q2
3 
B
C
A
S3
 
20
15
 
N
ik
pa
y1
59
 
A
ng
io
ge
ne
si
s1
37
 
rs
72
12
79
8 
 
C
/T
 
18
q2
1 
PM
A
IP
1-
M
C
4R
 
20
15
 
N
ik
pa
y1
59
 
Le
pt
in
 si
gn
al
in
g,
 
ob
es
ity
13
7  
rs
66
31
29
 
 
A
/G
 
19
p1
3 
LD
LR
- 
SM
A
R
C
A
4 
20
09
 
K
at
hi
re
sa
n9
6   
LD
L 
ch
ol
es
te
ro
l18
1  
rs
11
22
60
8 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  K
ra
ru
p,
10
4  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  R
ip
at
ti,
18
0  
B
ol
to
n,
21
 H
ug
he
s8
3  
G
/T
 
 
 
 
 
 
rs
22
28
67
1 
 
T/
C
 
19
q1
3 
A
PO
E-
A
PO
C
1 
 
20
11
 
IB
C
 5
0K
 C
A
D
 
C
on
so
rti
um
87
 
LD
L 
ch
ol
es
te
ro
l18
1  
rs
20
75
65
0 
K
ra
ru
p,
10
4  B
jo
rn
ss
on
19
 
G
/A
 
 
 
 
 
 
rs
44
59
25
 
B
jo
rn
ss
on
19
 
C
/T
 
19
q1
3 
ZN
F5
07
-
LO
C
40
06
84
 
20
15
 
N
ik
pa
y1
59
 
 
rs
12
97
64
11
 
 
T/
A
 
19
p1
3 
D
O
T1
L-
A
P3
D
1-
SF
3A
2*
* 
20
15
 
H
iro
ka
w
a7
4  
 
rs
35
79
28
72
 
 
 
21
q2
2 
 
M
R
PS
6-
SL
C
5A
3-
K
C
N
E2
 
20
09
 
K
at
hi
re
sa
n9
6   
M
ai
nt
ai
ns
 c
ar
di
ac
 
el
ec
tri
c 
st
ab
ili
ty
13
7  
rs
99
82
60
1 
La
bo
s,1
12
 T
ra
ga
nt
e,
23
1  M
eg
a,
13
9  
B
jo
rn
ss
on
,19
 T
ik
ka
ne
n,
22
7  R
ip
at
ti,
18
0  
B
ol
to
n,
21
 H
ug
he
s8
3  
T/
C
 
 
 
 
 
 
rs
72
78
20
4 
B
ol
to
n2
1  
G
/A
 
  
 
 
 
 
rs
93
05
54
5 
 
A
/G
 
22
q1
1 
PO
M
12
1L
9P
-
A
D
O
R
A
2A
 
20
15
 
N
ik
pa
y1
59
 
In
fa
rc
t-s
pa
rin
g 
ef
fe
ct
s1
37
 
rs
18
08
03
 
 
G
/T
 
* 
As
so
ci
at
io
n 
on
ly
 in
 H
an
 C
hi
ne
se
. *
* 
As
so
ci
at
io
n 
on
ly
 in
 J
ap
an
es
e.
 S
N
P 
in
di
ca
te
s s
in
gl
e 
nu
cl
eo
tid
e 
po
ly
m
or
ph
is
m
; W
TC
C
C
, W
el
lc
om
e 
Tr
us
t C
as
e 
C
on
tr
ol
 C
on
so
rt
iu
m
; L
D
L,
 lo
w
-d
en
sit
y 
lip
op
ro
te
in
; S
M
C
, s
m
oo
th
 m
us
cl
e 
ce
ll.
 D
at
a 
co
lle
ct
ed
 fr
om
 th
e 
or
ig
in
al
 
ar
tic
le
s,9
,3
4,
39
,4
0,
50
,6
6,
71
,7
4,
87
,9
6,
12
3,
13
6,
15
9,
17
5,
19
0,
19
8,
23
4,
24
3,
25
7  1
9,
21
,8
3,
10
4,
11
2,
13
9,
18
0,
22
7,
23
1  f
ro
m
 R
ob
er
ts,
18
1  a
nd
 M
cP
he
rs
on
 e
t a
l.1
37
     
 
 
35 
2.7. Differences in pathophysiology and clinical characteristics 
between STEMI and NSTEMI  
The MI subtypes STEMI and NSTEMI differ from each other in pathophysiology, in 
treatment (section 2.5.), and in patient characteristics.  
In STEMI, the thrombus is mostly occlusive, sustained, and fibrin-rich, whereas in 
NSTEMI the thrombus is platelet-rich, only partially occlusive, dynamic, or even 
absent,172 and detaching microthrombi may embolize downstream.11 Furthermore, in 
NSTEMI, length of plaque rupture is smaller,229 and plaques are more calcified.78 As can 
be suspected from the changes in ECG, infarct size in NSTEMI is smaller.192 Recurrent 
MIs are more frequently of the same type as was the first MI.186  
Patients with STEMI often have angiographically milder disease than do patients with 
NSTEMI, and are typically younger and more likely to be men and smokers.17,127 
Furthermore, among STEMI patients, diabetes, dyslipidemia, and hypertension are less 
common than among NSTEMI patients.127 
Although many characteristics differ between STEMI and NSTEMI patients, no 
difference has emerged in the genetics of these conditions. Many of the known CAD 
variants have been analyzed with respect to ACS subtype, with no difference appearing in 
their frequencies between STEMI and NSTEMI patients.242   
2.8. Prediction of CAD, MI and outcome 
2.8.1. Traditional risk-prediction tools 
 
Several tools have been developed to evaluate risk for CVD. Cardiovascular risk 
assessment tools predict the likelihood of developing any specified cardiovascular 
condition during a predefined time period. These tools include scores predicting CAD 
among a healthy population as well as tools designed for predicting recurrence or 
mortality risk among patients already suffering from ACS (Table 3).  
The best-known and most widely used tool to predict cardiovascular events among 
healthy people is the Framingham risk score.255 It estimates the 10-year-risk for CAD by 
calculating risk points for gender, age, total or LDL cholesterol, HDL cholesterol, blood 
pressure, diabetes, and smoking. The Framingham score is useful in primary prevention 
and in showing patients the impact of each life-style-related risk factor.  
The Global Registry of Acute Coronary Events (GRACE) risk scores are designed to 
predict risk for in-hospital death after admission with ACS61 and risk for a recurrent MI 
or CVD death within six months after an MI.47,56 The GRACE scores serve in the initial 
presentation to distinguish patients most likely to benefit from an invasive strategy. These 
scores include eight to nine variables such as age, heart rate, systolic blood pressure, 
creatinine level, severity of heart failure (Killip class), possible cardiac arrest at 
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presentation, ST-segment deviation, and cardiac enzymes. GRACE scores have been 
validated by many studies and meta-analyses, showing good discriminatory performance 
across all types of ACS for short- and long-term prognosis.36 In the patients undergoing 
PCI for ACS, however, the GRACE six-month post-discharge score was not as reliable as 
in patients receiving medical therapy only.2  
The risk score of the Thrombolysis in Myocardial Infarction Study Group (TIMI)8 
evaluates the risk of patients with UAP/NSTEMI to develop severe recurrent ischemia 
requiring urgent revascularization, to develop another MI, or to die within a fortnight. The 
seven predictor variables of TIMI score include age ≥65 years, presence of at least three 
CAD risk factors, prior coronary artery stenosis of 50% or more, ST-segment deviation at 
presentation, at least two episodes of angina in the past 24 hours, prior use of aspirin for 
at least a week, and elevated cardiac biomarkers. Some of these factors are also included 
in the GRACE scores. In TIMI, the variables were unweighted, and the high-risk patients 
were excluded in calculating the score, both actions reducing its discriminatory 
performance.13 On the other hand, the TIMI score is easy to use.  
The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using 
Integrilin Therapy (PURSUIT)20 risk score assesses mortality and a composite event of 
MI or death within one month. It includes age, sex, high Canadian Cardiovascular Society 
Angina class in the previous six weeks, admission heart rate, ST-segment depression, and 
signs of heart failure. The discriminatory performance of the PURSUIT score is evaluated 
as achieving the same level as the GRACE scores.258  
The Evaluation of the Methods and Management of Acute Coronary Events 
(EMMACE)45 risk score includes age, systolic blood pressure, and heart rate and 
evaluates the risk of dying within 30 days after acute MI. The Simple Risk Index (SRI) 
includes age, admission systolic blood pressure, and heart rate and predicts 30-day 
mortality in STEMI patients.149 The Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Coronary Arteries (GUSTO)30 score evaluates one-
year mortality in 30-day survivors of STEMI and includes age, heart rate, left ventricular 
ejection fraction, previous infarction, and in-hospital heart failure with pulmonary edema.  
Although the end-point, time-frame, and the target group vary from score to score, all 
these risk scores overlap, and the variables included are mostly the same, although they 
emphasize different points of view. The complexity of the scores and number of variables 
varies.  Despite the fact that all the scores perform quite well, for example the C-statistic 
of GRACE score being ≥0.80 in a large validation study,36 the actual utilization of the 
scores in everyday practice remains unclear. To evaluate the risk, however, these tools 
combine only clinical features and risk factors, not genetic information. 
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2.8.2. Risk prediction using genetic information 
 
Intensive research has recently focused on genetic risk prediction tools for CAD and MI. 
Genetic risk scores (GRS) are calculated as the sum or the mean of previously suggested 
risk variants. A GRS can be unweighted, or it can be weighted, for example with 
published effect estimates. For the GRSs, the SNPs are chosen from among the risk 
SNPs, which are established by GWAS with large sample sizes for the disease in 
question. Use of weighted scores instead of unweighted is supported by previous 
research.25 Using an unweighted score would assume that each has an effect of the same 
size, which does not apply in a multifactorial disease.  
The capability of GRSs to predict CAD in a healthy population has been promising, 
and studies on that subject are emerging. The Atherosclerosis Risk in Communities 
(ARIC) Study presented a risk score of candidate genes back in 2007;148 it showed an 
association with incident CAD in a healthy population. Since then, the variants included 
in most GRSs are selected from among the results from large GWAS, and, as new risk 
variants are identified, the number of risk variants included in the GRSs is growing. GRSs 
including SNPs of genome-wide significant association with CAD have improved CAD 
prediction over traditional risk factors and family history and helped to identify 
individuals at high risk for the first CAD event in healthy populations in different 
geographic areas (Table 4).21,83,104,180,227 Table 2 shows the SNPs included in these risk 
scores. In a recent study, a genome-scale GRS of over 49 000 SNPs included additionally 
SNPs of less than genome-wide significant association with CAD.1 This GRS improved 
CAD risk prediction at population level independently of clinical risk factors and the 
study showed that men in the highest quintile of GRS attained 10% cumulative CAD risk 
12 to 18 years earlier than men in the lowest quintile of GRS.  
An individual with a genetic predisposition for ACS may also be at high risk for 
recurrent events, since the medical treatment may be ineffective in reducing genetic risk 
that led to the initial event.112 Including either a single SNP or a combination of SNPs in a 
risk prediction model could help in recognizing individuals at high genetic risk and be 
helpful in secondary prevention. Among the ACS patients, loci at chromosomes 9p21 
(rs1333049),28 9q34.2 (rs579459),242 1p13.3 (rs599839),49 and 1q41 (rs17465637)49 have 
been linked to subsequent cardiovascular outcomes. Of the SNPs, inclusion of locus 
9p2128 and locus 9q34.2242 in the clinical risk prediction model for recurrent MI or 
cardiac death after MI improved the classification. The locus at chromosome 9p21.3 was 
also associated with better five-year survival of high-risk patients with STEMI.212 Some 
of the other known CAD risk SNPs have been tested for association for recurrence 
separately, but with no linkage to survival.242  
Results regarding GRSs and recurrent ACS are inconsistent. In a study by Tragante 
and collegues, a 30-SNP GRS was significantly associated with recurrence risk in a sex- 
and age- adjusted model.231 Perhaps due to the limited number of events, this association 
was not significant after multivariable adjustments, however. 
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Table 4. Summary of published GRSs with differing numbers of CAD risk SNPs identified 
in GWAS. 
Risk score Year Population N N of 
events 
End-point Median 
follow-up 
time 
(years) 
N of 
SNPs 
Predicting CAD in 
healthy population 
       
Ripatti 180 2010 Healthy 30 725 1 264 CAD 10.7  13 
Hughes83 2012 Healthy men 4 818 1 736 CAD 18 8-15 
Tikkanen227 2013 Healthy 24 124 1 552 CVD 12  28 
Bolton21 2013 Healthy 840 180 CAD 15  27 
Krarup104 2015 Healthy 6 041 374 CAD 11.6 (mean) 45 
Mega139 2015 Healthy 48 421 3 477 CAD  27 
Predicting recurrent 
ACS/MI 
       
Tragante231 2013 MI 153 72 Recurrent MI 8  30 
Labos112 2015 ACS 3 503 389 Composite of all-cause 
mortality, recurrent MI, 
cardiac re-hospitalization 
1  30 
Mega139 2015 MI 2 878  
+1 999 
320+2
29 
CAD 4.9 + 2  27 
Predicting other CAD 
related end-points 
       
Björnsson19 2015 CAD 
patients 
8 622  CAD extent  50 
Hernesniemi73 2015 Autopsy 1 035 306 Sudden death due to CAD  153 
SNP indicates single nucleotide polymorphism; CAD, coronary artery disease; CVD, 
cardiovascular disease; ACS, acute coronary syndrome; MI, myocardial infarction. Data 
collected from original articles.19,21,73,83,104,112,139,180,227,231 
In a study consisting of several different cohorts, Mega and colleagues reported that 
higher risk quintiles of 27-SNP GRS were associated with raised risk of both incident and 
recurrent CAD events.139 In this study, the follow-up time for recurrence differed across 
cohorts, the mean values ranging from 2.0 to 4.9 years.139 The population in these cohorts 
was highly selected because of its randomized controlled trial study design. The GRS was 
used as risk quintiles, differing from the practice in other studies. The survival analysis 
was also conducted separately in statin-user and non-user groups.   
In a study of three pooled cohorts comprising 3 503 ACS patients, a 30-SNP GRS was 
not associated with outcome within one year after ACS,112 nor did the addition of the 
GRS to the GRACE risk model improve risk prediction. In this study, the GRS served as 
a continuous variable, and the patient population was more heterogeneous due to the 
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study design, when compared to the study by Mega and colleagues.139 Follow-up time 
was also limited to one year.  
Furthermore, GRSs comprising CAD risk variants have also shown an association 
with extent of atherosclerosis measured in coronary angiography19 and in sudden death73 
caused by CAD.  
 
2.9. Other manifestations of CVD 
2.9.1. Peripheral artery disease 
In PAD, atherosclerosis narrows the arteries typically in the lower extremities and 
weakens the oxygen supply to the peripheral tissues. Patients with PAD suffer from 
claudication or critical limb ischemia, but PAD can also present with atypical symptoms 
or be asymptomatic.35,217 The diagnosis is based on abnormal ankle brachial index (ABI), 
since blood flow to the periphery weakens. PAD is associated with morbidity comprising 
impaired functional capacity, frailty, impaired quality of life, and high medical-care costs. 
Atherosclerotic PAD is highly prevalent worldwide, affecting more than 200 million 
people.54 From 2000 to 2010, the number of patients suffering from PAD increased by 
almost 30% in low- and middle-income countries and by 13.1% in high-income 
countries.54 The prevalence of PAD increases with age, and PAD affects a substantial 
proportion of the elderly.35  
The clinical risk factors for CAD and atherosclerotic PAD progression are the same: 
dyslipidemia, hypertension, smoking and diabetes mellitus. In addition, age is an 
independent predictor for PAD progression as determined by ABI decline.97,217 No clear 
association between PAD and gender exists. However, more severe disease 
manifestations occur in men.35 In women, PAD appears more often with atypical pain.133 
Smoking seems to be associated with PAD at an even higher relative risk level than for 
CAD.53 PAD is associated with increased morbidity and mortality from incident coronary 
and cerebrovascular disease.35  
In contrast to CAD, in which thrombosis in unstable plaque leads to ACS, acute 
events in PAD are uncommon. Instead, in PAD, the symptoms slowly worsen as the 
arteries progressively narrow. This signals that both environmental and genetic factors 
contribute to PAD risk in a somewhat different manner than they contribute to CAD and 
to ACS. Genetic factors contributing to PAD may act independently of clinical risk 
factors.107  
When compared to CAD, fewer genetic markers linked to PAD have emerged. This 
may result from the greater clinical and genetic heterogeneity of PAD. Additionally, the 
role of environmental factors is proposed to be greater in PAD than in CAD 
development.113 Genetic factors are suggested to affect especially early-onset PAD.107  
A few SNPs have shown an association with PAD in GWAS.62,70,102,107,108,154,224 The 
first identified CAD risk locus 9p21  (rs10757278),70 a nicotine-dependence related SNP 
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(rs1051730) in chromosome 15,224 and a variant linked to abdominal aortic aneurysm in 
chromosome 9 (rs7025486)62 contribute to PAD. Additionally, rs1902341102 near the 
OSBPL gene and rs653178108 near the SH2B3-ATXN gene were associated with PAD. In a 
meta-analysis, a variant near PAX2 (rs6584389) associated with PAD (P<1x10-6), but the 
significance did not achieve genome-wide level.154 Stemming from the greater 
heterogeneity, GWASs of larger sample sizes are required to aid in the discovery of new 
PAD risk variants. Additionally, phenotypic stratification of patients with PAD may be 
useful in detecting new genetic risk variants, as well.107  
Although the genetic contribution to PAD is suggested differ from that of CAD/MI, 
some of the identified PAD risk variants associate also with CAD/MI or with other 
manifestations of CVD, such as abdominal aortic aneurysms.62 This indicates that 
common genetic risk factors are present across the subtypes of CVD, i.e. the risk variants 
are pleiotropic.107  
2.9.2. Stroke 
In stroke, blood flow to a certain area of the brain is decreased due to blockade or 
spontaneous rupture of blood vessels, which causes a loss of functional brain tissue.250 
This results in symptoms such as trouble with speech, visual loss, sudden weakness, 
dizziness, or headache.93 The diagnosis of stroke is primarily based on typical symptoms 
and CT imaging. If the symptoms are transient, i.e. they last less than 24 hours, the 
condition is referred to as transient ischemic attack (TIA). Depending on the mechanism, 
a stroke can be either ischemic or hemorrhagic. An ischemic stroke, 87% of cases,151 is 
caused by a lack of blood supply to the small arteries supplying localized areas of the 
brain. This lack can result from a number of processes, including atherosclerotic small 
vessel disease causing occlusion and ischemia downstream in the brain, large vessel 
disease causing occlusion or emboli, cardioembolic stroke, or from infrequent 
mechanisms such as cervical artery dissections.163 In hemorrhagic stroke, 13% of cases,151 
a vessel supplying the brain ruptures and blood accumulates in either the sub-arachnoid 
space or intra-cerebral space of the brain. 
Annually 15 million people suffer from stroke.151 In relation to the treatment and 
prevention of traditional risk factors, the stroke incidence has decreased by 42% in high-
income countries during the last four decades. However, in low- and middle-income 
countries, stroke incidence has increased rapidly.51 As in the case of CAD and PAD, 
stroke is also associated with functional impairment, impaired quality of life, and high 
health-care costs. As many as one-fourth of stroke patients become dependent on 
receiving help to function in their everyday lives, and almost half suffer from cognitive 
deficits.151  
As in CAD and PAD, the traditional risk factors, such as sex, smoking, hypertension, 
diabetes, and dyslipidemia greatly affect the risk for stroke. Two-thirds of strokes are first 
events, thus the prevention and treatment of risk factors is crucial.141 Stroke is noticeably 
more frequent among women than among men. Hypertension affects stroke risk more 
than CAD or PAD risk.151  
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Not all strokes, however, can be explained by risk factors alone, but, as in the other 
manifestations of atherosclerosis, the genetics also matter.170 Up to 50% of an 
individual’s stroke risk is evaluated to depend on genetics, but the heritability estimates 
depend on age, sex, and stroke subtype.230 In addition to genetic variants linked to certain 
risk factors, many other genetic variants affect the risk for stroke.64,65,67,77,88,99,171,232,233,254 
For example, common variants previously linked to atrial fibrillation, 4q25 near PITX2 
and 16q22 near ZFHX3, have been associated with ischemic stroke.65,67 Some of the risk 
variants for ischemic stroke are pleiotropic and additionally confer the risk for CAD. 
Among these are the first discovered CAD risk variant on chromosome 9p2164 and the 
MI-linked variant at the ABO locus.254 Moreover, a large meta-analysis analyzed the 
known CAD risk variants for association with ischemic stroke, particularly large artery 
stroke, and vice versa, and reported several additional shared genetic risk variants.44 
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3. Aims of the study 
The main aims of this study were to evaluate the importance of clinical risk factors and 
genetics in predicting the recurrence and prognosis of ACS and its subtypes. More 
precisely, the objectives were as follows.  
 
 
1) To collect a cohort of consecutive patients undergoing coronary angiography in 
Helsinki University Central Hospital, to describe their demographics, angiographic 
findings, and the stability of their CAD and to analyze their risk factors and the frequency 
of revascularization (I) 
 
 
2) To test the ability of a GRS in predicting recurrent ACS and CAD mortality (II) 
 
 
3) To determine the differences between NSTEMI and STEMI patients in clinical factors 
and genetics (III) 
 
 
4) To assess whether the genetic variant discovered in Study III is associated with adverse 
outcome, cardiovascular risk factors, or other manifestations of atherosclerosis, such as 
PAD (IV) 
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4. Methods 
4.1. Design of the substudies 
Study I 
An observational cohort study of consecutive coronary angiography patients purposed to 
evaluate their risk-factor profiles, disease stability, and severity, as well as the 
revascularization strategy.  
 
Study II 
A prospective, observational cohort study to analyze the capability of GRSs to predict 
recurrent ACS and CAD mortality.  
 
Study III 
A GWAS to search for risk variants exclusively for STEMI/NSTEMI in a case-control 
setting. The finding was replicated in another case-control cohort and in a prospective 
cohort.  
 
Study IV 
A prospective, observational cohort study to evaluate outcome, cardiovascular risk 
factors, and other manifestations of atherosclerosis in patients with or without risk alleles 
on chromosome 1p13.3 (rs656843). 
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4.2. Study cohorts 
The basis of Studies I to IV is the Corogene cohort. All methods and results are from the 
Corogene study, unless otherwise indicated. Patients from the Tampere Acute Coronary 
Syndrome Study (TACOS) and FINRISK cohorts are included in Studies III to IV to 
further test the discoveries of the Corogene Study (Table 5). Selected individuals from 
FINRISK cohorts served also as controls. Participants in all of these cohorts gave their 
written informed consent. The Ethics Committee of Helsinki University Hospital, Internal 
Medicine approved the research protocol for the Corogene study. The Ethics Committee 
of the National Institute of Welfare and the Coordinating Ethics Committee of the 
Helsinki and Uusimaa Hospital District approved the protocols of the FINRISK studies. 
The Ethics Committee at Tampere University Hospital approved the TACOS protocol.  
 
 
Table 5. Individuals included in Studies I-IV. 
 Corogene FINRISK TACOS 
N 5 294 23 036 998 
Study I 5 294   
Study II 2 090 with ACS    
Study III    
Discovery sample: Corogene 1 863 with MI of which 
1579 genotyped 
1 576 matched controls  
Replication I: TACOS  566 matched controls 564 genotyped 
MI patients 
Replication II: FINRISK           16 627 of which 848 
with MI 
 
Study IV    
Discovery sample: Corogene 1 768 genotyped ACS 
patients 
  
Replication: FINRISK  21 161 of which 439 
with PAD 
 
TACOS indicates the Tampere Acute Coronary Syndrome Study; ACS, acute coronary syndrome; 
MI, myocardial infarction; PAD, peripheral artery disease.  
  
 
46 
4.2.1. Corogene (I-IV) 
The basis of this study was the Corogene cohort, which comprised 5 294 consecutive 
angiography patients in Helsinki University Central Hospital between June 2006 and 
March 2008. The Hospital District of Helsinki and Uusimaa serves more than 1.5 million 
inhabitants. In the hospitals of this area, a total of over 4800 coronary angiograms are 
performed annually, and Helsinki University Central Hospital performs 75%.  
After excluding patients with other than Finnish citizenship, repeated angiograms for 
patients already included in the study, and patients with low hemoglobin, recent blood 
transfusion, or previous heart transplantation (511, 8.8%), the cohort comprised 5 294 
patients (91.2% of all angiography patients). The patients were treated with standard drug 
regimens and procedures.  
 
Patient classification 
According to the angiography findings and the symptoms, these patients were classified 
into four groups: 
Group 1. No CAD in angiographic evaluation. The angiogram in these patients was 
required to reveal either normal or mildly (up to 50%) obstructed coronary 
arteries. (I) 
Group 2. Stable CAD. The requirement was significant stenosis (more than 50%) in at 
least one coronary artery and stable symptoms. (I) 
Group 3. ACS. Criteria for inclusion were chest pain typical for ischemia combined 
with typical ECG changes, biomarker measurements (TnT, CKMBm), and 
at least one significantly (more than 50%) obstructed coronary artery. (I to 
IV) 
Group 4. Other ischemic events. Patients had elevated biomarkers, symptoms typical 
for ACS, and possible ECG changes, but no significant coronary artery 
stenosis. (I) 
 
Data collection 
The patient questionnaire provided information on height, symptoms of CAD, other CVD 
manifestations, and other diseases. Additionally, collected information covered family 
history for CAD, medications, smoking, alcohol intake, drug abuse, allergies, special 
diets, social situation, and home nursing. Current smoking was defined as smoking or 
having quit smoking within six months before study inclusion. Ex-smoking was 
considered as having quit smoking more than six months before the inclusion.  
Patient records, a cardiological data log, and the cardiac-surgery database provided 
information on height, risk factors, prior cardiac disease and operations, comorbidities, 
medication, chest x-ray, ECG, echocardiography, angiography, PCI, and CABG. 
Hypertension, dyslipidemia, and diabetes (types 1 and 2) were defined as fulfilling the 
criteria for the medication for these disorders.  
Blood samples for serum and plasma analyses were drawn from the arterial line 
during the angiography. Laboratory values collected included complete blood count, 
CRP, blood lipids, glucose, HbA1c, liver enzymes, bilirubin, activated partial 
thromboplastin time, renal values (urea, creatinine), electrolytes, CK, cardiac markers 
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such as b-type n-terminal natriuretic propeptide (proBNP), TnT, CKMBm, and D-dimer. 
Blood samples additionally served for extraction of deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA). Glomerular filtration rate (GFR) for each patient was estimated 
from serum creatinine by the Modification of Diet in Renal Disease Study (MDRD) 
equation.114 
Patients of the Corogene Study were followed up until death or by the end of the year 
2012. Statistics Finland (Tilastokeskus) provided the mortality data. The National 
Hospital Discharge Registry provided the information on ACS recurrence rate, and 
incidence of PAD, cerebral infarction, and atherosclerotic aortic disease. 
4.2.2. TACOS (III) 
The TACOS Study comprises ACS patients admitted to Tampere University Hospital 
between January 2002 and March 2003.160 The diagnostic criteria for ACS in the TACOS 
and Corogene studies were analogous, except for the use of TnI (TnI>0.2 mg/L) in 
TACOS whereas Corogene used TnT and CKMBm. Patients transferred from another 
department within the hospital or initially treated for ACS in other hospitals were 
excluded. The study sample comprised 998 MI patients, of whom 343 had STEMI, and 
655 had NSTEMI. Of these, 564 MI patients had adequate clinical and adequate 
genotypic information for analysis in Study III. 
4.2.3 FINRISK (III-IV) 
FINRISK is a repetitive cohort study for which a new cohort is collected once every five 
years. The FINRISK cohorts reveal trends in cardiovascular risk factors in Finland.237,238 
A random sample of 25- to 74-year-old inhabitants, representing different regions, 
genders, and age-groups, participated in each cohort by invitation. Altogether 23 036 
individuals took part in the FINRISK 1992, 1997, 2002, and 2007 cohorts.  
FINRISK cohorts provided both cases and controls for Studies III and IV. 
Additionally, the gene expression levels were tested from 513 individuals recruited during 
2007 for the Dietary, Lifestyle, and Genetic determinants of Obesity and Metabolic 
syndrome (DILGOM) study, an extension of the FINRISK 2007 study. Of these samples, 
372 served also as controls for the Corogene MI cases in the GWAS in Study III.  
In Study III, controls for the Corogene MI patients (discovery sample) were selected 
from among participants living in the Helsinki-Vantaa region from the FINRISK 1997, 
2002, and 2007 studies by use of risk set sampling. Independently for each Corogene MI 
case, two sex- and birth cohort (+- 5 years) -matched controls were chosen from all 
FINRISK participants. Individuals were suitable as controls if they were free of CVD at 
the time of ACS diagnosis of the chosen matched case. One FINRISK participant could 
serve as a control several times. For TACOS MI patients (replication sample I), controls 
came from the FINRISK 1992, 1997, 2002, and 2007 cohorts. The controls were required 
to be born in Pirkanmaa to match the geographical region of the cases in TACOS.  
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FINRISK participants with an MI diagnosis in The National Hospital Discharge 
Registry and with their genotype data available were the selected cases for replication 
sample II. All the other genotyped FINRISK patients were included in the analysis of 
prospective setting, with the exception of participants with prevalent MI, insufficient data 
on phenotype, or who were among the individuals serving as controls in the discovery or 
in replication sample I. Replication sample II eventually comprised 16 627 participants, 
with 163 cases of incident NSTEMI, 99 cases of incident STEMI and 222 cases of 
incident MI with unspecified ST-segment status.  
Study IV included FINRISK participants with both genotype and PAD phenotype 
information available, the individuals with incident PAD serving as cases and other 
subjects as controls, with the exception of prevalent PAD cases. The National Hospital 
Discharge Registry provided the information on prevalence and incidence of PAD. 
4.3 Definitions of study end-points  
Total mortality, CVD mortality, and CAD mortality (II, IV) 
CVD mortality was considered as death from either CAD, cerebral infarction, PAD, or 
aortic aneurysm or dissection. CAD-related death was defined according to the 
International Classification of Diseases (ICD-10) codes I20-I25, I46, R96, or R98 as the 
direct or as the underlying cause of death, or I21-I22 as the contributing cause of death. 
Death from cerebral infarction was considered as ICD-10 codes I63-I64 and death from 
aortic aneurysm as I71. PAD-related death was defined as I70.2, I73.9, and vascular 
complications of diabetes E10.5, E11.5, E12.5, E13.5, or E14.5. The definition for CAD-
related death and use of the Causes of Death Registry from Statistics Finland have been 
validated.162  
 
Recurrent ACS (II, IV) 
Recurrent ACS was defined as I20.0, I21, or I22 as the main or as the additional 
diagnosis. Events occurring 28 days after initial hospitalization for ACS were considered 
in the Corogene cohort as recurrent events. In Study II, a composite event of recurrent 
ACS or CAD death was formed. In Study IV, CAD-related cause of death was considered 
as recurrent ACS.  
 
ACS subtype (III) 
The ACS patients were classified into groups of UAP, NSTEMI, and STEMI according to 
changes in ECG and release of cardiac biomarkers. The criteria for classification were 
uniform with the international ACS definitions (section 2.2) supplemented with the 
criterion of >50% obstruction of at least one coronary artery. In patients with typical 
STEMI symptoms, ECG, and biomarker release (CKMBm more than 50 mg/l), but with 
no coronary obstruction, the criterion of significant stenosis observed in the angiography 
was discarded; these patients were still classified as having STEMI. Study III included 
only patients with either STEMI or NSTEMI.  
 
  
 
49 
Other manifestations of CVD (IV) 
PAD was defined as I70.2, I73.9, or vascular complications of diabetes E10.5, E11.5, 
E12.5, E13.5, or E14.5. In the Corogene cohort, PAD was defined as incident, if no 
claudication symptoms were reported at study inclusion. Cerebral infarction was 
classified as ICD-10 codes I63-164, and atherosclerotic aortic disease, including 
aneurysms and dissections, as code I71. 
4.4 Genotyping 
Corogene (I-IV) 
The Corogene study participants were genotyped at the Wellcome Trust Sanger Institute, 
Cambridge, United Kingdom, with the Illumina HumanHap 610-Quad SNP Array. 
Exclusion criteria for individuals were as follows: a low genotyping success rate < 95%, 
differing reported and genotype-determined gender, and excess relatedness. Additional 
exclusion criteria for SNPs were a genotyping success rate < 95%, low MAF < 1%, or P < 
10−6 for an exact test of Hardy-Weinberg equilibrium. Only autosomal SNPs were 
included.  
The dataset was completed by genotype imputation using IMPUTE v2.2.282 with the 
1000 Genomes Project integrated variant set. Uncommon variants (MAF < 5%) and 
variants with imputation score < 0.6 were excluded. For the GWAS in Study III, any 
SNPs with P < 0.05 for Pearson's X2 test for genotype missingness between cases and 
controls were excluded.  
In total, genetic information was available for 1 768 ACS patients, including 1 579 MI 
cases (962 NSTEMI, 614 STEMI, 3 MI with unspecified ST-segment status).  
 
FINRISK (III-IV) 
The FINRISK subjects were genotyped with the Affymetrix 6.0 (330), Illumina 610K11 
(1 845), HumanCoreExome (19 910), and OmniExpress (2 542) genotyping arrays. 
Exclusion criteria were the same as in the genotyping of the Corogene cohort. The data 
were imputed with IMPUTE v2.3.213 with 1000 Genomes Phase 3 haplotypes, which 
was supplemented with a haplotype set of 2 000 Finnish haplotypes. 
 
TACOS (III) 
The MI patients of the TACOS cohort were genotyped by standard procedures at the 
Institute of Molecular Medicine Finland (FIMM), Helsinki, Finland, with the Sequenom 
MassARRAY iPLEX platform. A total of 74 samples were genotyped twice to ensure the 
quality of genotyping, and concordance was 100%. Of the TACOS cohort, 390 patients 
with NSTEMI and 174 patients with STEMI were successfully genotyped.  
 
Gene expression (III) 
Gene expression was examined from leukocytes of the participants with the Illumina HT-
12 expression array.89 All of the samples were analyzed twice. The correlation between 
the two measurements was examined by measuring the Pearson’s product moment 
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correlation coefficient (P) and Spearman’s rank correlation coefficient (ρ) from 
normalized values. Poor correlation (P < 0.94 or ρ < 0.60) between the paired samples led 
to exclusion.  
4.5. Statistical methods 
4.5.1. Statistical tests  
Numbers are presented as mean ± standard deviation (SD) for normally distributed scale 
variables and as median [interquartile range (IQR)] for other continuous variables.  The 
number and percentage is shown for each categorical variable. Hazard ratios (HR) and 
odds ratios (OR) accompanied by 95% confidence intervals (CI) are reported. Chi-square 
tests determined the statistical difference between groups for categorical variables. 
Student’s t-test for independent samples served to analyze normally distributed scale 
variables, and the Kruskal-Wallis test to compare other continuous variables. A P < 0.05 
denoted the limit for statistical significance.  
Cox regression analysis served for survival analysis of longitudinal data in Studies II 
to IV, and logistic regression analysis for analysis of cross-sectional data, including 
associations between genetic variants and MI phenotypes. All models were first 
conducted as age- and sex-adjusted and then, if appropriate, multivariable adjusted. An 
additive genetic model was assumed for all association tests in Studies II to IV. The 
Hosmer-Lemeshow goodness-of-fit test determined calibration of the logistic regression 
models. The proportional hazards assumption was met and was analyzed with use of 
'cox.zph' function60,222,223 of the “survival” package for R v3.2.2 with P > 0.05 for all end-
points tested. Linear regression served for studying associations between genetic variants 
and gene expression levels, with probe intensities set as the dependent variables. 
Multivariable adjustment in Study II comprised history of hypertension, dyslipidemia, 
diabetes, or prior MI, smoking, subtype of ACS, 3-vessel disease, and any congestion 
observed in chest radiography in addition to age and sex. Interaction terms for 
interactions between genetic and clinical variables were tested in the multivariable 
models, but no interactions achieved significance.  
In Study III, the Cox proportional hazards analysis was stratified by geographical 
region, the year and the genotyping batch of the cohort; sex, systolic blood pressure, 
blood pressure medication, total cholesterol, HDL cholesterol, current smoking, and 
prevalent diabetes served as covariates. In the case-control setting in Study III, all the MI 
patients, and STEMI and NSTEMI patients as groups, were contrasted with controls with 
age, gender, and the 10 first genomic principal components as covariates. Since in 
replication sample I the controls were matched only for geographical area, not for age or 
sex, these also could not serve as covariates in the analysis.164  
Multivariable adjustment in Study IV included age, sex, hypertension, dyslipidemia, 
diabetes, smoking, 3-vessel disease, and NSTEMI in the Corogene cohort; and age, sex, 
hypertension, dyslipidemia, diabetes, smoking, and the genotyping cohort and year of the 
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cohort in the FINRISK study. No interactions appeared in the multivariable models in 
Study IV. The 10 first genomic principal components were included in the Cox regression 
analyses, but they showed no significance in the analysis, and thus they were not included 
in the final multivariable analyses. 
 
The 87 046 directly genotyped SNPs in approximate linkage equilibrium allowed 
calculation of the genome-wide principal components for the MI patients of the Corogene 
study with EIGENSTRAT v4.2.167 The principal components served in Studies III to IV. 
Inverse-variance weighted fixed- and random-effects meta-analysis models served in 
combining the results of the logistic regression models with GWAMA v2.1.124 The 
Bayesian model comparison analysis method15 served in comparison of association 
statistics between MI subtypes.  
The statistical analysis tool was IBM SPSS 20.0 for baseline factors in Studies I to IV, 
for all logistic regression models and Cox regression models including single SNPs in 
Study II, and for all Cox regression models in Study IV. In Study III, PLINK v1.07168 was 
the tool for analyzing directly genotyped variants and SNPTEST v2.4.0129 for the imputed 
variants. SNPTEST v2.4.0 additionally allowed investigation of associations between 
genetic variants and gene expression levels. The survival package223 for R173 v2.15.1 (II) 
and v3.0.2 (III) served as the tool for Cox proportional hazards models with GRSs in 
Study II and for all Cox proportional hazards models in Study III.  
4.5.2. Calculation of GRS 
The 153 SNPs reported in the CARDIOGRAMplusC4D Study40 were chosen to be 
combined as GRSs in Study II. They were first evaluated separately in age- and sex-
adjusted Cox proportional hazards models. End-points considered were recurrent ACS, 
CAD death, and a composite of recurrent ACS and CAD death. After Bonferroni 
correction for multiple comparisons, the corrected P-value threshold for statistical 
significance was 0.05/153=3.27E-4.  
These 153 SNPs were then combined to form three different, partially overlapping 
GRSs. GRS32 comprised 32 SNPs already discovered even before the 
CARDIOGRAMplusC4D Study. GRS47 included the SNPs in the GRS32, supplemented 
by the risk variants that the CARDIOGRAMplusC4D Study uncovered in 2013. GRS153 
combined all these 153 SNPs, consisting of both established risk variants and a broader 
set of independent variants (r2<0.2) strongly associated with CAD at a 5% false discovery 
rate (FDR) threshold. The GRS values for each individual were calculated as a weighted 
mean by summing the alleles of each variant, weighting them with the effect sizes 
reported in the CARDIOGRAMplusC4D Study and dividing by the number of variants 
included.  
Evaluation of clinical value of the GRS involved receiver operating characteristics 
(ROC) curves and area under the curve (AUC) calculation (survival package of R 
v2.12.1). 
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5. Results 
5.1. Overall patient characteristics in the Corogene cohort (I) 
 
Figure 4 Patients in the Corogene study. CAD, coronary artery disease; ACS, acute coronary 
syndrome.  
 
Figure 4 shows the distribution of the 5 294 patients among the study groups. The most 
common reason for a coronary angiography during the study period was ACS, and 
diagnosing stable CAD was the second most common. Of the 2 090 ACS patients, 227 
(10.9%) had UAP, 1 134 (54.3%) NSTEMI, and 729 (34.9%) STEMI (II). Almost one-
fourth of the patients (1207, 23%) showed no signs of obstructive CAD in the coronary 
angiography. These patients suffered from stable or atypical chest pain caused by valvular 
disease, cardiomyopathy, or conditions other than CAD. Coronary angiography was 
essential to exclude coronary obstruction as a cause for their chest pain symptoms. The 
patients evaluated as having an acute ischemic event other than ACS suffered from 
conditions such as type 2 MI, myocarditis, or Takotsubo cardiomyopathy. 
The mean age of the cohort was 65.6 years, and 63.8% of the patients were male. 
These patients with a greater number of diseased coronary arteries were older and more 
likely to be men (Table 6) (S.V. et al., unpublished results). They were also more likely to 
suffer from other manifestations of atherosclerosis such as TIA, stroke, or claudication, 
and to have undergone prior revascularization procedures (PCI or CABG). Furthermore, 
the prevalence of traditional risk factors rose along with the number of diseased 
coronaries.  
Of the risk factors, diabetes mellitus and smoking were more frequent among male 
patients. In contrast, female patients were more likely to be hypertensive; dyslipidemia 
was equally common in both genders. The finding of no obstructive CAD in the coronary 
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angiography was much more frequent in women than in men. In evaluation by age group, 
the prevalence of hypertension, dyslipidemia, and diabetes increased with age, but 
smoking was more common among younger patients undergoing angiography (I, 
supplementary material). 
 
Table 6. Patient characteristics by disease severity.  
  CAD severity by coronary angiography 
 All patients No CAD <50% 
obstruction 
1VD 2VD 3VD 
Number of patients 5 294 902 522 1 360 1 037 1 469 
Gender (men) 3 379 (63.8) 421 (46.7) 250 (47.9) 897 (66.0) 718 (69.2) 1 091 (74.3) 
Age (years) 65.6 ? 11.1 60.2 ? 11.1 66.2 ? 9.8 63.4 ? 
11.2 
66.9 ? 10.9 69.6 ? 10.0 
Body mass index (kg/m2) 27.4 ? 4.8 27.1 ? 5.0 27.3 ? 5.4 27.3 ? 4.8 27.5 ? 4.6 27.4 ? 4.5 
Hypertension  3 515 (66.4) 493 (54.7) 361 (69.2) 853 (62.7) 732 (70.6) 1 074 (73.1) 
Dyslipidemia 3 721 (70.3) 465 (51.7) 362 (69.5) 927 (68.3) 805 (77.8) 1 160 (79.1) 
Diabetes 1 054 (19.9) 71 (7.9) 94 (18.0) 209 (15.4) 235 (22.7) 445 (30.3) 
Smoking 3 160 (59.7) 431 (47.8) 300 (57.9) 842 (62.1) 668 (65.0) 918 (63.0) 
Arrhythmia 1 398 (26.4) 358 (39.7) 184 (35.2) 248 (18.2) 225 (21.7) 381 (25.9) 
Prior MI 1 094 (20.7) 37 (4.1) 46 (8.8) 209 (15.4) 267 (25.8) 535 (36.6) 
Cardiomyopathy 263 (5.0) 117 (13.1) 42 (8.1) 37 (2.8) 25 (2.5) 41 (2.9) 
Other CVD symptoms       
Claudication 537 (10.1) 41 (4.6) 65 (12.5) 74 /5.5) 118 (11.5) 237 (16.2) 
Stroke/ TIA 662 (12.5) 86 (9.6) 67 (12.8) 146 (10.8) 127 (12.3) 236 (16.2) 
Prior cardiovascular 
operations 
      
Prior PCI 671 (12.7) 1 (0.1) 11 (2.1) 153 (11.3) 205 (19.8) 301 (20.5) 
Prior CABG 500 (9.4) 0 2 (0.4) 12 (0.9) 68 (6.6) 418 (28.5) 
Other 417 (7.9) 65 (7.2) 46 (8.8) 47 (3.5) 81 (7.8) 178 (12.1) 
Prior vascular operations       
Lower extremity 184 (3.5) 5 (0.6) 19 (3.7) 15 (1.1) 48 (4.7) 97 (6.6) 
Other 106 (2.0) 9 (1.0) 9 (1.7) 14 (1.0) 16 (1.6) 58 (4.0) 
Mean ± standard deviation is shown for continuous variables (age and body mass index) and 
number (%) for categorical variables (all others). Percentage is calculated of those with 
information available in each group. CAD indicates coronary artery disease; 1VD, 1-vessel 
disease; MI, myocardial infarction; CVD, cardiovascular disease; TIA, transient ischemic attack; 
PCI, percutaneous coronary intervention; CABG, coronary artery by-pass grafting. 
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During the study hospitalization or electively after the discharge, 681 (38%) patients 
with stable CAD underwent PCI and 377 (21%) underwent CABG (Table 7) (S.V. et al., 
unpublished results). Of the ACS patients, the proportion undergoing PCI was almost 
double (1484, 71%). CABG was performed for 312 (15%) patients with ACS. No 
revascularization procedures were performed for patients with other acute ischemic 
events or without coronary obstructions <50% of lumen diameter. Of all 5 294 patients, 2 
854 (54%) were revascularized. 
 
Table 7. The revascularization of the Corogene patients. 
 Total All revascularized PCI CABG 
All patients 5 294 2 854 (53.9) 2 165 (40.9) 689 (13.0) 
All patients with 
CAD/ACS 
3 883 2 854 (73.5) 2 165 (55.8) 689 (17.7) 
ACS 2 090 1 796 (85.9) 1 484 (71.0) 312 (14.9) 
Stable CAD 1 793 1 058 (59.0) 681 (38.0) 377 (21.0) 
No CAD/ Other 
ischemic event 
1 411 0 0 0 
Number (% of the total in each row) is shown for all. ACS indicates acute coronary syndrome; 
CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery 
by-pass grafting.  
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5.2. ACS patients (II) 
5.2.1. Recurrent ACS during follow-up  
Of all 2 090 ACS patients, 263 (12.6%) had recurrent ACS, and 473 (22.6%) experienced 
a composite event of recurrent ACS or CAD death. The recurrent ACS presented within a 
median 595 days (IQR 130-1 284) and the composite event of recurrent ACS or CAD 
death within a median 428 days (IQR 63- 1 134) (Figure 5). In most cases, the type of 
recurrent ACS was NSTEACS (89 NSTEMI, 95 UAP, 58 STEMI). In 21 cases, 
information on the recurrent ACS type was unavailable. 
Of the clinical risk factors, older age, female gender, history of hypertension, and 
diabetes mellitus were associated with recurrent ACS (II). Also greater atherosclerotic 
burden, indicated by 3-vessel disease in coronary angiography, prior MI, previous 
procedures of PCI or CABG, were linked to higher risk of ACS recurrence. They also 
more often used medication linked to difficult symptoms, such as long-acting nitrates and 
diuretics. Patients with recurrent ACS were slightly less frequently on statin therapy than 
were those without recurrent events. Those with recurrent ACS were more likely to have 
either NSTEMI or UAP as the index ACS. 
The same features that were associated with recurrent ACS were also associated with 
the composite event of recurrent ACS and CAD death, in addition to higher heart rate, 
higher CRP, pulmonary congestion, and PCI during initial hospitalization (II, 
supplementary material). These patients also less often received low-molecular-weight 
heparin during their initial hospitalization, and less often used clopidogrel, but more often 
warfarin.  
 
Figure 5 Cumulative hazard curve for recurrent ACS, age- and sex-adjusted. ACS indicates 
acute coronary syndrome.  
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5.2.2. Mortality of the ACS patients  
In all 2 090 ACS patients, median follow-up time was 1 964 days (IQR 1 542- 2 169), and 
of these patients, the 1 635 survivors had a median follow-up time of 2 076 days (IQR  
1 929-2 231). A total of 455 (21.8%) died within a median 406 (IQR 44-874) days after 
study inclusion; the figure for 30-day mortality was 71 (3.4%) and 1-year mortality was 
156 (7.5%).  
Of the non-survivors, 357 (17.1%) had a CVD-related cause of death, and 259 (12.4 
%) had a CAD-related cause of death. Median time to CVD death was 331 days (IQR 14-
829) and to CAD death 419 (IQR 23- 1 200). Figure 6 shows the hazard curve for CAD 
mortality, adjusted for age and sex. 
Clinical factors associated with CAD death were similar to those associated with 
recurrent ACS: older age, female gender, history of hypertension or diabetes mellitus, 
indicators of greater atherosclerotic burden, arrhythmias, and pulmonary congestion. Of 
the medications, warfarin, diuretics, long-acting nitrates, AT-receptor blockers, and 
calcium antagonists were associated with CAD mortality. Conversely, PCI or CABG 
during study hospitalization, and medical treatment with statins, clopidogrel, aspirin, 
ACE-inhibitors, and low molecular-weight heparin were associated with longer survival 
(S.V. et al., unpublished results).  
 
 
 
Figure 6 Cumulative hazard curve for CAD-related death, age- and sex-adjusted. CAD 
indicates coronary artery disease. 
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5.2.3. Single SNP associations with outcome and with risk factors in ACS 
patients  
All the 153 SNPs with either genome-wide significant or suggestive association with 
CAD were tested for associations for recurrent ACS, CAD death, and the composite event 
of recurrent ACS and CAD death in age- and sex-adjusted Cox models (II, supplementary 
material). Of all these SNPs, 10 associated nominally with recurrent ACS, eight with 
CAD death during the follow-up period, and seven with the composite event. After 
Bonferroni correction, only locus rs2832227 in chromosome 21 near the TAKL1 gene was 
significant (HR 1.509, 95% CI 1.160-1.964, P=0.002 for recurrent ACS; HR 1.468, 95% 
CI 1.202-1.792, P<0.001 for the composite event). After multivariable adjustment for age, 
sex, history of hypertension, dyslipidemia, diabetes, prior MI, smoking, subtype of ACS, 
3-vessel disease, and pulmonary congestion, this locus remained significant (HR 1.591, 
95 % CI 1.204-2.101, P=0.001 for recurrent ACS; HR 1.459, 95 % CI 1.176-1.810, 
P=0.001 for the composite event).  
The loci for 9p21 (rs1333049), 1q41 (rs17465637), and ABO (rs495828) were 
associated with none of the end-points.  
The 47 SNPs with genome-wide significant associations with CAD were tested for 
associations with hypertension, dyslipidemia, diabetes mellitus, and smoking. Before 
Bonferroni correction, four SNPs associated with hypertension (rs12205331, rs11191447, 
rs9326246, rs9982601), five with dyslipidemia (rs11206510, rs602633, rs12205331, 
rs1122608, rs1561198), two with diabetes mellitus (rs974819, rs9982601) and six with 
smoking (rs2048327, rs4773144, rs9515203, rs2895811, rs2954029, rs9319428). Of these 
SNPs, only rs2895811, near the HHIPL1 gene, was significant after Bonferroni correction 
(OR 0.778, 95% CI 0.671-0.902, P=0.001) (II, supplementary material). 
5.2.4. GRS associations with outcome in ACS patients  
The GRSs were tested for associations with outcome in age- and sex-adjusted and in 
multivariable-adjusted Cox models. Both GRS32 and GRS47 were significantly 
associated with recurrent ACS in age- and sex-adjusted models (HR 1.210, 95% CI 
1.059-1.382, P=0.005; HR 1.199, 95% CI 1.046-1.374, P=0.009, respectively) and in 
multivariable-adjusted models (HR 1.165, 95% CI 1.008-1.346, P=0.038; HR 1.169, 95% 
CI 1.009-1.355, P=0.037, respectively). Figure 7 shows the multivariable-adjusted hazard 
curves for GRS47, divided into two groups determined by median value. GRS32 was also 
associated with the composite event of recurrent ACS or CAD death in the age- and sex-
adjusted model, but not in the multivariable-adjusted model (HR 1.121, 95% CI 1.121-
1.239, P=0.026; HR 1.093, 95% CI 0.982-1.122, P=0.102, respectively). GRS153 had no 
association with either end-point.  
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Figure 7 Multivariable-adjusted hazard curves for recurrent ACS. Separate lines for patients 
with low GRS (below the median) and high GRS (above the median). Adjustments for 
age, gender, hypertension, dyslipidemia, diabetes, prior MI, smoking, subtype of 
ACS, 3-vessel disease, and pulmonary congestion.  ACS indicates acute coronary 
syndrome; GRS, genetic risk score.  
After confirming GRS32 and GRS47 to be associated with recurrent ACS independent 
of clinical risk factors, estimation of the clinical value of GRSs was based on ROC curves 
(II). A clinical risk estimation model was formed by combining age, sex, hypertension, 
dyslipidemia, diabetes, prior myocardial infarction, smoking, subtype of myocardial 
infarction, 3-vessel disease, and pulmonary congestion in Cox regression. The AUC for 
this clinical model was 0.690. The GRSs were then added to this regression model of 
clinical factors. The AUC for the clinical model supplemented by GRS32 was 0.694. 
When the clinical model was supplemented by GRS47, the AUC was 0.696. Thus, the 
addition of either GRS to the clinical model did not improve the AUC clinically 
significantly.  
 
5.2.5. GRS associations with subtype of ACS and clinical factors 
All of the GRS correlated inversely with STEMI in age- and sex-adjusted logistic 
regression analysis (OR 0.380, 95% CI 0.171-0.843, P=0.017 for GRS32; OR 0.357, 95% 
CI 0.133-0.959, P=0.041 for GRS47; and OR 0.089, 95% CI 0.015-0.523, P=0.007 for 
GRS153) (II). The unadjusted mean values of the GRSs were only marginally higher in 
NSTEMI than in STEMI patients (for GRS32, 1.09 vs. 1.08, P=0.114, for GRS47 1.11 vs. 
1.10, P=0.259, and for GRS153 1.10 vs. 1.09, P=0.140) (S.V. et al., unpublished results). 
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Both GRS32 and GRS47 were, in addition, inversely associated with smoking (OR 
0.340, 95% CI 0.148-0.779, P=0.011 for GRS32; P=0.004, OR 0.217, 95% CI 0.077-
0.616 for GRS47), and GRS153 with dyslipidemia (OR 0.210, 95% CI 1.375-53.95, 
P=0.021). GRS32 showed a positive correlation with 3-vessel disease (OR 2.574, 95% CI 
1.124-5.896, P=0.025) (II).  
5.3. Differences between STEMI and NSTEMI patients (III) 
5.3.1. Clinical characteristics 
The STEMI and NSTEMI patients differed in the prevalence of all risk factors, 
comorbidities and their CAD severity (Table 8) (S.V. et al., unpublished results). The 
STEMI patients were younger, and more likely to be men, and to be smokers than were 
the NSTEMI patients. Hypertension, dyslipidemia, diabetes, and comorbidities were all 
less common in STEMI patients. Of note, the prevalence of 3-vessel disease was almost 
twice as high in NSTEMI patients as in STEMI patients.  
 
Table 8. Characteristics and comparison of STEMI and NSTEMI patients in the Corogene 
cohort. 
 NSTEMI STEMI P 
N 1134 729  
Age 67.5 ? 11.5 63.3 ? 12.0 <0.001 
BMI 27.6 ? 5.0 27.3 ? 4.6 0.176 
Heart rate 67.8 ? 15.3 73.1 ? 18.1 <0.001 
Male gender 776 (68.4) 532 (73.0) 0.036 
Hypertension 797 (70.3) 415 (57.1) <0.001 
Dyslipidemia 852 (75.1) 439 (60.3) <0.001 
Diabetes 258 (22.8) 89 (12.2) <0.001 
Smoking 685 (60.9) 487 (68.0) 0.002 
Arrhythmia 223(19.8) 104 (14.4) 0.003 
Prior MI 271 (24.1) 105 (14.5) <0.001 
Claudication 130 (11.6) 45 (6.2) <0.001 
Stroke/TIA 160 (14.3) 59 (8.1) <0.001 
3-vessel disease 468 (41.3) 157 (21.5) <0.001 
Number (percentage within each genotype) is shown for categorical variables. Mean ? standard 
deviation is shown for continuous variables. NSTEMI, non-ST elevation myocardial infarction; 
STEMI, ST-elevation myocardial infarction; BMI, body mass index; MI, myocardial infarction; 
TIA, transient ischemic attack.  
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5.3.2. Genetic variants associated with NSTEMI in GWAS 
Genetic information was available in the Corogene Study for 1 579 MI cases. Most 
patients (962, 60.9%) had NSTEMI, and 614 (38.9%) had STEMI. At the time of the 
analyses, only 3 patients with MI were of unspecified ST-segment status. 
In GWAS, the threshold for statistical significance was pre-specified at P<5.0E-8. In 
the analysis of the Corogene Study, two directly genotyped and 14 imputed variants on 
chromosome 1p13.3 showed a genome-wide significant association with NSTEMI. Of the 
directly genotyped variants, rs656843 was the most significant (OR for the minor allele 
1.63, 95% CI 1.38-1.93, P=1.22E-8) (Table 9). Of the imputed variants, rs2764553 
achieved the highest level of statistical significance (OR for the minor allele 1.62, 95% CI 
1.24-1.63, P=1.63E-9). Conversely, no variant showed any significant association with 
STEMI or with both MI subtypes combined.  
 The directly genotyped variant rs656843 was chosen for replication in the TACOS 
sample. Here, rs656843 showed an association with NSTEMI (OR for the minor allele 
1.44, 95% CI 1.12 to 1.86, P = 0.005). Moreover, rs656843 was associated statistically 
significantly with MIs combined (OR 1.38, 95% CI 1.10 to 1.74, P=0.006). No 
association between rs656843 and STEMI was observable (OR 1.27, 95% CI 0.91–1.77, 
P=0.16).  
When the Corogene and TACOS case-control samples were combined for further 
analysis, again, rs656843 was associated with NSTEMI, but not with STEMI or MIs 
combined.  
In the FINRISK sample of prospective design, rs656843 showed no significant 
association with NSTEMI, STEMI, or with STEMI and NSTEMI combined. The 
estimated HR for NSTEMI was in a similar direction of association (HR 1.13, 95% CI 
0.84–1.51, P=0.43), however. 
Variants associated with NSTEMI, including also rs656843, are located in the LD 
block that contains the genes damage-regulated autophagy modulator 2 (DRAM2), 
CEPT1, and the 3´ end of DENND2D. In previous works, rs1335645 between CEPT1 and 
DENND2D has been associated with plasma gammaglutamyltransferase (GGT) levels,31 
and rs599839, near PSRC1 and SORT1, has been associated with CAD risk and high LDL 
levels.251 No associations appeared between rs656843 and either GGT or LDL in controls 
of the Corogene sample (P=0.11 for GGT; P=0.22 for LDL). Rs656843 was confirmed to 
be independent from these SNPs by calculation of the correlation between rs656843 and 
the previously reported SNPs (r2 < 0.05).  
When tested in healthy controls, DRAM2 expression level in blood leukocytes was 
associated with a majority of the variants near 1p13.3; however, not with rs656843 
(expression probe ILMN_1808634). The most statistically significant variant was 
rs325927 (P=1.50E-12).  
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Table 9. Associations of rs656843 with NSTEMI, STEMI, and MI combined in the study 
samples.  
Sample N OR (95 % CI) P 
Discovery sample: Corogene    
NSTEMI 962 1.63 (1.38-1.93) 1.22E-8 
STEMI 614 1.07 (0.88–1.29) 0.50 
STEMI, NSTEMI and 
unspecified MI combined 
1 579 1.33 (1.15–1.54) 1.27E-4 
Controls 1 576   
Replication I: TACOS    
NSTEMI 389 1.44 (1.12-1.86) 0.0049 
STEMI  173 1.27 (0.91-1.77) 0.16 
MI combined 562 1.38 (1.10-1.74) 0.0062 
Controls 566   
Corogene + TACOS    
NSTEMI 1 351 1.57 (1.36-1.81) 3.11E-10  
STEMI  787 1.11 (0.94-1.31) 0.200 
STEMI, NSTEMI and 
unspecified MI combined 
2 124 1.34 (1.19-1.52)  2.58E-6 
Controls 2 124   
Replication II: FINRISK  HR (95% CI)  
NSTEMI 163 1.13 (0.84–1.51) 0.43 
STEMI  99 0.97 (0.65-1.43) 0.87 
STEMI, NSTEMI and 
unspecified MI combined 
484 1.00(0.84-1.19) 0.98 
Controls 16 143   
Corogene sample analyzed by logistic regression adjusted for age, sex, and the first ten genomic 
principal components, and FINRISK by Cox proportional hazards model stratified by study year, 
geographical region, and genotyping batch; with gender, systolic blood pressure, blood pressure 
medication, total cholesterol, HDL-cholesterol, smoking and diabetes as covariates. OR indicates 
odds ratio; CI, confidence interval; HR, hazard ratio; NSTEMI, non-ST elevation myocardial 
infarction; STEMI, ST-elevation myocardial infarction; MI, myocardial infarction.  
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5.3.3. Association of previously reported CAD/MI risk loci with NSTEMI and 
STEMI (III) 
The previously confirmed CAD/MI-related SNPs were tested for association with MI and 
selectively STEMI or NSTEMI in a case-control setting. In this study, of these 50 variants 
16 were associated with MI (P<0.05). Among these were also five SNPs near 
CDKN2A/CDKN2B on chromosome 9p21 (OR for the minor allele of rs10757278 1.28, 
95% CI 1.15–1.43, P=1.25E-5). No statistically significant differences were detectable in 
MAF between any of the 50 SNPs and STEMI/NSTEMI, when the Bonferroni correction 
for multiple testing was used (in all tests P>0.001). Interestingly, rs514659 in the ABO 
gene showed the most significant difference (MAF in STEMI patients 48.1%, and 43.3% 
in NSTEMI patients, P=0.007). 
5.4. Associations of variant rs656843 at 1p13.3 with 
cardiovascular risk factors, adverse outcome, and other 
manifestations of atherosclerosis (IV) 
5.4.1. Associations of rs656843 genotypes with clinical characteristics  
The genotype of rs656843 was available for 1 768 patients, of which 56 (3.2%) 
patients were homozygotes for minor allele C (Table 10).  Two-thirds of the patients (1 
171, 66.2%) were non-carriers of the risk allele, and 541 (30.6%) were heterozygotes. 
The MAF of rs656843 was 0.185.  
All risk factors and clinical characteristics except ACS subtypes and claudication were 
evenly distributed across the genotypes. Claudication symptoms were more common in 
patients with the CC genotype of rs656843 than with CT and TT genotypes (21.4%, 
11.2%, and 8.8%, P=0.004) (Table 10). The association of rs656843 with claudication 
remained significant in an age- and sex-adjusted logistic regression model (OR 1.51, 95% 
CI 1.15-1.97, P=0.003) and in a multivariable-adjusted logistic regression model (OR 
1.48, 95% CI 1.11-1.96, P=0.007): adjustments were for age, gender, hypertension, 
dyslipidemia, diabetes, smoking, 3-vessel disease, and NSTEMI.  
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Table 10. Clinical characteristics according to rs656843 genotypes and chi-square test 
results.  
 N Rs656843 genotype P 
  TT CT CC  
All patients 1 768 1 171  541  56   
Age 66.8  (57.7-75.2) 66.8 (57.8-75.2) 66.2 (57.0-74.9) 65.8 (57.4-75.8) 0.748 
Men 1 225 (69.3) 802 (68.5) 377 (69.7) 46 (82.1) 0.093 
NSTEMI 957 (54.1) 597 (51.0) 326 (60.3) 34 (60.7) 0.001 
STEMI 616 (34.8) 440 (37.6) 156 (28.8) 20 (35.7) 0.002 
3-vessel 
disease 
599 (33.9) 395 (33.7) 183 (33.8) 21 (37.5) 0.844 
Hypertension 1 167 (66.0) 770 (65.8) 352 (65.1) 45 (80.4) 0.068 
Diabetes 337 (19.1) 225 (19.2) 103 (19.0) 9 (16.1) 0.843 
Dyslipidemia 1 253 (70.9) 821 (70.2) 388 (71.7) 44 (78.6) 0.354 
Smoking  1 095 (61.9) 728 (62.8) 330 (61.5) 37 (67.3) 0.659 
Claudication 174 (9.8) 102 (8.8) 60 (11.2) 12 (21.4) 0.004 
Stroke/ TIA 212 (12.0) 144 (12.4) 60 (11.3) 8 (14.3) 0.707 
Number (percentage within each genotype) is shown for categorical variables. Median 
(interquartile range) is shown for age. NSTEMI indicates non-ST-elevation myocardial 
infarction; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack.  
5.4.2. Associations of rs656843 with outcome and other manifestations of 
CVD 
A strong association was detectable between rs656843 and PAD: In addition to 
claudication symptoms, rs656843 (C-allele) was associated with incidence of PAD during 
the follow-up (age- and sex-adjusted HR 1.66, 95% CI 1.12-2.45, P=0.012 in Cox 
regression). After adjusting for age, gender, hypertension, dyslipidemia, diabetes, 
smoking, 3-vessel disease, and NSTEMI, this association remained significant (1.75, 95% 
CI 1.19-2.59, P=0.005) in ACS patients of the Corogene cohort.  
Cox regression analysis revealed no association between rs656843 and recurrent ACS, 
cerebral infarction, or aortic aneurysms. Furthermore, rs656843 was not associated with 
total, CVD, or CAD mortality.  
Because PAD diagnosis was determined by the first PAD-related contact with health 
care during the follow-up, the diagnosis also reflects the overall burden of PAD 
symptoms in all study patients. The association of rs656843 with incident and prevalent 
PAD diagnoses combined was thus calculated. In multivariable-adjusted Cox analysis, 
rs656843 showed a significant association with PAD in all patients (HR 1.84, 95% 1.40-
2.41, P=1.061E-5).  
The analyses were additionally conducted in the FINRISK population cohort to 
determine whether the association between rs656843 and PAD was also apparent at 
population level. Of note, the FINRISK cohort differed from the Corogene cohort 
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markedly: the individuals were healthier and younger, since the individuals initially 
included were aged from 25 to 74 years. No correlation between rs656843 and incident 
PAD was detectable in the FINRISK cohort (HR 1.06, 95% CI 0.89-1.25, P=0.522 in Cox 
regression adjusted for genotyping cohort and sex; multivariable-adjusted HR 1.03, 95% 
CI 0.87-1.22, P=0.703, adjustments for sex, genotyping cohort, cohort year, hypertension, 
dyslipidemia, and diabetes). 
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6. Discussion 
This study evaluated the characteristics of a Finnish cohort of consecutive patients who 
underwent coronary angiography between 2006 and 2008. GRSs formed of known CAD 
risk variants were found to be associated with recurrent ACS independent of clinical 
factors. When compared to other studies evaluating GRS in recurrent ACS prediction, the 
GRS with 47 confirmed CAD variants included the greatest number of risk variants. Both 
clinical and genetic differences between STEMI and NSTEMI patients were studied and 
GWAS analysis revealed variants, including rs656843, at a locus near 1p13.3, to be 
associated nominally with NSTEMI. Finally, this variant showed a significant association 
also with PAD in ACS patients.  
6.1. Cohort evaluation 
The Corogene cohort includes comprehensive clinical information on more than 5 000 
consecutive patients who underwent coronary angiography. Information from patient 
records was supplemented with a questionnaire, laboratory tests, and in selected patients, 
even genotyping. Use of the Hospital Discharge registry and Causes of Death registry 
from Statistics Finland provided an objective follow-up. In contrast, in many other 
cohorts, the follow-up is conducted by regular visits or phone calls; thus their follow-up 
information is more subjective and may be incomplete.  
Other cohorts have initially included consecutive patients who underwent coronary 
angiography, but these cohorts have included only patients with ACS or stable CAD, and 
excluded patients with stable symptoms and without obstructive CAD in coronary 
angiography. Thus, only selected parts of the Corogene cohort can be compared to other 
studies. 
For an ACS cohort, the size of the study sample was acceptable. The Corogene cohort 
is approximately of the same size as other single-center ACS cohorts. However, for 
example, when compared to the genotyped cohort of the GRACE study,242 which also 
tests the association of genetic variants with the outcome of ACS, the Corogene cohort 
includes 30% fewer patients, and 40% fewer patients with available genetic information. 
In ACS patients, the proportion of STEMI was similar to that in previous studies, but the 
distribution to UAP and NSTEMI varies; in this study the proportion of NSTEMI was 
higher and, accordingly, the prevalence of UAP was lower than in the GRACE study.41,216 
The mortality rate of ACS patients in the Corogene study was lower (7.5% one-year 
all-cause mortality) than in some other European cohorts of consecutive ACS patients. 
For instance, in the GRACE cohort, collected in 2000-2002, the one-year all-cause 
mortality was almost double (14.8%) that of Corogene,216 whereas another cohort of 
NSTEACS patients, collected in the UK in 1998-1999, had an all-cause mortality rate 
also slightly higher (9.2%) than that of Corogene.215 Treatment has been rapidly 
improving, and most likely the timing of the Corogene study accounts for the difference 
in mortality rates. Evolution in the measurement assays of cardiac biomarkers probably 
explains the different proportions of the NSTEMI and UAP patients (section 2.2).  
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It is of interest whether the patients with stable or atypical angina symptoms might 
benefit from other, non-invasive coronary imaging options or from myocardial perfusion 
imaging. In the Corogene cohort, one-fourth of the patients needed coronary angiography 
to rule out CAD as the culprit in their chest pain symptoms and had either no 
atherosclerotic changes in their coronary arteries or only mild obstruction (<50%) (I). 
Only one-third of the patients with stable symptoms and obstructive CAD in angiography 
underwent PCI in the same session or electively later, after the index angiography, and 
only half of all patients were finally revascularized (I).  
Invasive coronary angiography has been the gold standard of coronary imaging for 
decades.115,188 It provides a view of the silhouette of the lumen of the coronary arteries 
while the contrast is administered. By means of invasive coronary angiography without 
further techniques such as intravascular ultrasound, the structure and pathology of the 
vessel wall cannot, however, be evaluated. Non-obstructive CAD may also demonstrate 
vulnerable lesions. They may lie within the vessel wall, and the atherosclerotic coronary 
arteries may be outward remodeled, so that the lumen diameter can be maintained as 
normal.117,228 Outward remodeling cannot be detected by coronary angiography, meaning 
that a significant atherosclerotic burden and possible vulnerable plaques may be missed. 
Of note, rupture of a vulnerable plaque may result in thrombosis, and ACS. In theory, 
diagnostics with coronary angiography alone may thus lead to slightly over-optimistic 
interpretation. Although among MI patients, revascularization occurs in the same session 
as the diagnostic coronary angiography, and is the key to ischemia treatment, the role of 
diagnostic coronary angiography in stable angina patients may be decreasing. 
At present, some of the patients included in the Corogene Study could possibly be 
examined less invasively, for example by CCTA.72 It provides information on the 
composition of the plaque.52 The sensitivity and the specificity have proven good in 
CCTA; the negative predictive value is high especially in patients with a low pre-test 
probability for CAD.91,143,169,185,206 Low-risk patients with stable or atypical chest pain 
could be diagnosed primarily with CCTA, whereas the invasive imaging method is 
preferable in patients with a high probability of CAD and always when immediate 
revascularization is essential.206 Non-invasive imaging offers benefits when compared to 
invasive angiography and its ever-present risk for complications. The most common 
complications in invasive angiography are pseudoaneurysm of the punction site, and 
dissection and thrombosis of the vessel.3 Both methods expose the patient to a risk for 
contrast reactions. However, the radiation dose is usually higher in CCTA than in 
invasive angiography,132 and not all patient groups are suitable for evaluation by 
CCTA.206 In evaluation of the hemodynamic significance of a plaque, the invasive 
angiography supplemented with measurement of fractional flow reserve is superior to 
CCTA.140,206 In addition to CCTA, other techniques for advanced imaging of CAD have 
also been developed, such as myocardial perfusion imaging which shows any ischemia 
present.  
The patients for the Corogene cohort were collected in 2006-2008. Since then, the 
newer, non-invasive CAD imaging methods have rapidly developed. It remains to be seen 
to what extent these methods can eventually substitute for the invasive diagnostic 
angiography. 
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6.2. Genetics affecting outcome of ACS patients 
In this study, both an individual SNP and GRSs formed of known CAD risk variants were 
associated with outcome (II). The risk variant for NSTEMI at 1p13 discovered in this 
study had no impact on post-ACS prognosis (II-III). Some genetic variants have been 
associated with the outcome earlier, but the evidence concerning any association between 
outcome and GRS has been conflicting (sections 2.6.1. and 2.8.2).  
Previously, the GRACE Genetics Study showed that known variants at chromosome 
9p2128 and at chromosome 9q34.2 (ABO gene region),242 both of which have been linked 
to CAD also in the Finnish population,180 predispose ACS patients to either recurrence or 
cardiac death during a 6-month follow-up. In the Corogene cohort, however, no 
correlation between these variants and the outcome emerged (II). Several explanations 
may exist for this finding. First, the Corogene cohort included substantially fewer 
genotyped ACS patients. Second, the GRACE Study focused on short-term recurrence 
and followed the patients for only 6 months, whereas the follow-up of the Corogene 
cohort was more than 5 years. Third, the effect size of each risk variant may vary across 
populations. Finally, the proxy SNP for ABO in the Corogene and in the GRACE Study 
differed. In addition to 9p21 and 9q34.2, also loci at 1p13.3 (rs599839) and at 1q41 
(rs17465637) can affect the prognosis of patients with prior MI.49 In the Corogene cohort, 
these loci showed no association with either recurrent ACS or with the composite end-
point of recurrent ACS and CAD death.  
The risk variant rs656843 for NSTEMI at 1p13.3, discovered in this study, had no 
impact on the prognosis after ACS (III-IV). The minor alleles of the variants previously 
shown to be associated with survival or recurrence are nevertheless considerably more 
common. Of note, while the MAF of the variant rs1333049 on chromosome 9p21 is 0.48 
to 0.53, and the MAF of the variant rs579459, on chromosome 9q34.2 near the ABO gene, 
is 0.21, the MAF of rs656843 is only 0.15. Thus the C-allele of rs656843 is quite 
uncommon. The potential effect of an allele this uncommon on recurrence/survival may 
be so modest that it is undetectable in a cohort of only 1768 genotyped patients. 
In addition to the 47 confirmed CAD risk SNPs, also over 100 susceptibility loci for 
CAD were analyzed for this study. In these analyses, locus rs2832227 for the gene 
TAK1L, on chromosome 21, was associated with recurrent ACS and with the composite 
end-point even after correction for multiple testing and multivariable adjustments for 
clinical factors (II). This locus is one of the suggestive loci from FDR analysis of the 
CARDIOGRAMplusC4D study, not reaching the genome-wide significance level. 
Earlier, this locus rs2832227 has been linked to dilated cardiomyopathy, but that finding 
could not be replicated.239 The association between rs2832227 and recurrent ACS, found 
in the current study, should be further confirmed.  
Studies concerning GRS associations with recurrent ACS are emerging. The results 
have been either negative within one year after ACS,112 suggestive in a sample with a 
limited number of events,231 or positive in patients selected for a randomized controlled 
trial concerning statin therapy.139 All of these scores include SNPs that overlap with the 
SNPs included in the GRSs of this study, but these scores include a maximum 30 CAD 
risk variants. The GRSs of this study comprise 32, 47, or 153 CAD risk variants and thus 
cover more of the genetic predisposition to CAD. A different focus with a shorter follow-
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up in the Labos study112 and the limited number of recurrent events in the Tragante 
study231 may account for the missing or relatively weak associations. Results from the 
Corogene study support the finding that GRSs comprising CAD risk SNPs can predict 
recurrence independently of clinical risk factors, and show this also in a heterogenic 
population.  
Although GRSs have been demonstrated as providing better risk estimations of CAD 
and first MI than do clinical factors in healthy or at-risk populations,1,38,83,104,180,221,227,235 
here, the addition of the GRS to a clinical risk model did not improve risk prediction for 
recurrent ACS clinically significantly (II). However, because MI frequency at population 
level is lower than the ACS recurrence rate, additional variables are necessary to improve 
the classification.  
A GRS that includes only the strongest variants is likely to perform better than a GRS 
comprising also variants with a weaker effect. In the present study, GRS153 showed no 
association with either recurrent ACS or with the composite of recurrent ACS and CAD 
death, although it covers a larger proportion of genetic predisposition to CAD than does 
either GRS32 or GRS47 (II). GRS153 most likely included some false positives, as it also 
included variants that were strongly, but not genome-wide significantly, associated with 
CAD. This weakens its prediction capability. Furthermore, the genetic variants first 
discovered are the most common and their association with CAD is the strongest.  
Bjornsson et al found that a GRS comprising CAD risk SNPs correlates with the 
presence of multivessel disease.19 In the Corogene cohort, this finding was confirmed in a 
Finnish population, as the GRS32 showed an association with 3-vessel disease. In fact, 
CAD-related SNPs from large-scale GWAS studies are suggested to be linked primarily 
with atherosclerosis and less with MI.181 Not only genetic background but also the 
pathophysiology behind atherosclerosis and MI differs, thrombosis in particular being 
more important in MI pathophysiology than in CAD. That the only variant related to MI 
but not to CAD is the ABO blood-type gene further supports this theory. Whereas 
atherosclerosis slowly develops along with multiple risk factors and age, MI occurs in 
smokers and even in younger individuals with fewer risk factors, indicating a more 
sudden disease onset. 
Of the CAD-related SNPs included in the GRSs in this study, most act either 
independently of known risk factors, or their action is unknown, but 11 variants act 
through lipids and five through hypertension.182 Of note, none of these variants is known 
to associate with smoking.259 In this study, the GRSs were inversely associated with 
smoking, however (II). This finding suggests that to develop ACS, smoking patients may 
need a somewhat smaller genetic risk burden than do non-smoking patients. This 
emphasizes the value of smoking as an ACS risk factor.  
 To conclude, when compared to other studies concerning GRS in recurrent ACS 
prediction,112,139,231 the GRS with 47 confirmed CAD variants includes the largest number 
of risk variants. This GRS was associated with recurrent ACS in a heterogenic Finnish 
population of ACS patients. The GRS did not, however, improve the accuracy of 
prognosis prediction clinically significantly. Smoking, showing an inverse association 
with the GRS, may outweigh the importance of a genetic predisposition to CAD. 
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6.3. Differences between STEMI and NSTEMI patients 
Many clinical differences between STEMI and NSTEMI patients are widely 
acknowledged (section 2.7). The pathology behind these ACS subtypes also differs. In 
addition to confirming these clinical differences in a Finnish population, this study also 
revealed the first difference in genetic background between these two ACS subtypes by 
discovering a genetic variant rs656843 on chromosome 1p13.3 linked exclusively to 
NSTEMI (III). This finding could also be replicated in another case-control material, but 
not in the prospective setting. Additionally, in the cohort of ACS patients, the GRSs 
correlated inversely with STEMI, and thus positively with NSTEACS.  
Interestingly, 3-vessel disease is much more common in NSTEMI patients than in 
those with STEMI, indicating progressive atherosclerosis. Altogether the genetic, 
pathologic, and clinical differences suggest that the two MI subtypes may have somewhat 
different background mechanisms, NSTEMI possibly being more of a continuum to the 
slow process of stable CAD and STEMI arising from local plaques, plaque vulnerability, 
and thrombosis.  
The inability to confirm the association between rs656843 and NSTEMI in the 
prospective setting possibly results from less uniform diagnostic criteria, inclusion of MIs 
other than type 1, and a smaller number of cases than in the case-control samples. The 
case-control replication sample was collected by a single center and contained 389 
NSTEMI cases, but the 163 incident NSTEMI cases in the prospective sample were 
identified from hospital discharge registries.  
Of the CAD risk variants found before this study, only one (ABO) is a risk variant for 
MI and not for CAD. As none of the SNPs previously reported to be associated with CAD 
showed statistically significant differences between STEMI and NSTEMI patients, the 
genetic variants affecting CAD development predispose individuals similarly both to 
NSTEMI and to STEMI. Genetic differences between the MI subtypes may be 
responsible for the acute response to plaque rupture and coronary artery occlusion or to 
the structure of the plaque itself. Interestingly, in this study, it was the ABO gene that 
most closely approached statistical significance for a difference between STEMI and 
NSTEMI patients (III).  
Among ACS patients, the GRSs showed inverse association with STEMI and thus 
positive with NSTEACS (II). This association may in part be explained by the fact that 
CAD variants are related primarily to atherosclerosis. When compared to STEMI 
patients, patients suffering from NSTEMI are more likely to have multivessel disease.17 
In contrast, smokers tend to develop STEMI rather than NSTEMI.127  
In the large international GWAS meta-analyses, rs656843 showed no association with 
risk for CAD/MI.34,40,198 In those meta-analyses, one of the end-points was MI, i.e. 
NSTEMI and STEMI combined. Since the sample sizes in those cohorts were 
considerably larger than that of Corogene, it seems unlikely that phenotypic differences 
alone would explain why the meta-analyses found no association between rs656843 and 
CAD/MI. The association discovered in this study is possibly affected by some genetic or 
environmental factor that is somewhat common in Finland but unusual in other European 
populations.  
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To conclude, with both clinical and genetic differences between STEMI and NSTEMI 
patients were studied, GWAS revealed variants, including rs656843, at a locus near 
1p13.3, to be associated nominally with NSTEMI. The GRSs’ inverse correlation with 
STEMI and thus positive correlation with NSTEACS, the finding of a genetic variant 
linked nominally to NSTEMI, the known differences in pathophysiology of STEMI and 
NSTEMI, and the fact that patients with NSTEMI and STEMI present with different 
clinical risk-factor profiles all suggest that these two ACS subtypes may have somewhat 
different etiology. 
6.4. The new risk variant for NSTEMI predisposing to PAD? 
Some of the known CAD risk variants are pleiotropic and affect the development of more 
than one manifestation of atherosclerosis. Therefore the risk variant rs656843 for 
NSTEMI (III) was also studied for associations with other manifestations of CVD and 
cardiovascular risk factors in ACS patients. In this study, the variant rs656843 was, even 
after multivariable adjustments, associated with incident PAD, but only in ACS patients. 
These data suggest that the variant rs656843 at 1p13.3, in addition to affecting the 
development of NSTEMI, may also predispose to PAD (IV).  
The genetic contribution to PAD is evaluated as differing from that in CAD or MI 
development, perhaps with traditional risk factors such as smoking playing an even 
greater role than in CAD development.62,70 Still, these two conditions share several 
genetic variants affecting the development of both conditions.107 For example, the variant 
at 9p21, the same common variant that is linked to CAD and affects CAD prognosis, is 
additionally associated with PAD, abdominal aortic aneurysms, and stroke.70 This study 
suggests the variant rs656843 as a pleiotropic variant, affecting development of both 
NSTEMI and PAD, but this finding should be further confirmed (IV). Moreover, the 
rs656843 risk allele carriers differed only in terms of PAD incidence, whereas other 
clinical characteristics and risk factors were distributed evenly across the rs656843 
genotypes. Thus, the action of rs656843 may be independent from that of traditional CAD 
risk factors.  
The association between the variant rs656843 and incident PAD was significant only 
in the ACS patients (IV). In contrast, in a population sample of younger and healthier 
individuals, no such finding was confirmed. Substantially fewer PAD- than CAD-risk 
variants have emerged,62,70,102,107,108,154,224 probably because of both the greater clinical 
and genetic variance of PAD and the fact that environmental factors may have a stronger 
effect on PAD than on CAD development.113 Discovery of new risk variants for PAD will 
require GWAS of even larger sample sizes. Stratification of patients, for example by 
diabetes, has been suggested to group similar phenotypes of the disease.107 The inability 
to demonstrate any association between rs656843 and PAD in a population cohort, but 
only in a highly selected ACS cohort, may be the result of PAD’s dispersed clinical 
phenotype and genetics. Another reason for this may be the fact that PAD usually 
develops in quite old age: some of the carriers of the minor allele in the population cohort 
will develop PAD later in life.  
  
 
71 
Most of the SNPs at 1p13.3 associated with NSTEMI in GWAS, but not rs656843, 
showed an association with the DRAM2 expression (III). DRAM2 is suggested to 
contribute to autophagy induction.260 Autophagy is a process that affects cellular 
homeostasis and can promote either cell survival or cell death. For example, in 
postmitotic cells such as vascular SMCs, endothelial cells, and cardiomyocytes, 
autophagy mediates survival and function.131,187,213 In many vascular diseases, including 
atherosclerosis and restenosis, the process of autophagy is altered.131 Enhanced and 
diminished autophagy both are harmful and may contribute to senescence and 
atherogenesis in vascular SMCs.63,213 Furthermore, autophagy may also have an impact 
on sensitivity to ischemia-reperfusion injury in the myocardium.59 The exact function of 
DRAM2 needs further elucidation, however.  
DRAM2 is expressed at least in the heart,256 in skeletal muscles,122 and in the tibial 
artery wall.122 The Genotype-Tissue Expression (GTEx) database122 has also reported 
rs656843 as being associated with expression of DRAM2, with the minor allele C 
reducing its expression. Instead of being causal, the association between rs656843 and 
DRAM2 expression may be coincidental. 
Patients with PAD more closely resemble patients with NSTEMI than those with 
STEMI. They are older, have more risk factors, and their symptoms worsen slowly, 
whereas disease onset in STEMI is usually sudden, and not all STEMI patients have any 
chest pain symptoms before the actual STEMI. Patients with PAD have atherosclerosis 
throughout their peripheral vessels, comparable to NSTEMI patients’ tendency to have 
more than one obstructed coronary. The association between genetic variants linked to 
DRAM2 and PAD must, however, be confirmed in other cohorts.   
 
6.5. Limitations of the study 
 
Some limitations can be found in this study. The Corogene cohort is of Finnish origin, 
and thus it reflects best the Finnish health care system and treatment systems in addition 
to patients’ clinical and genetic characteristics. Before the results can be generalized, they 
should be validated in other populations. The size of the cohort and the proportion of the 
genotyped patients can be viewed critically. 
Regardless of inclusion of all the consecutive patients undergoing coronary 
angiography, these patients are not thoroughly representative sample of all ACS patients. 
A considerable number of patients are treated conservatively in the same region and thus 
are not included in the study. Those ACS patients undergoing no angiography are usually 
older, have more comorbidities, and need more help in everyday life. In particular, they 
have a poorer prognosis. Thus, the survival rate of the ACS patients in the present study 
can be considered somewhat over-optimistic. Conversely, this study is a good reflection 
of those ACS patients evaluated as likely to benefit from invasive treatment.  
In the Corogene study, patients with less than 50% stenosis were not considered to 
have CAD. Although most likely a considerable proportion of the patients truly had no 
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atherosclerosis in their coronary arteries, the group also included patients with mildly 
obstructed coronaries. Assuming that a vulnerable plaque can lie inside the vessel wall 
and obstruct the vessel less than 50% if at all, patients with these kinds of plaques 
actually still have CAD, although CAD may cause no symptoms before the onset of ACS. 
The most effective medical therapy for these kinds of patients would be crucial to prevent 
further obstruction and ACS. Thus, the classification in the Corogene Study may be 
considered marginally misleading, however, it was as accurate as was considered possible 
and necessary at the time of the collection of the cohort.  
The age-range in the Corogene cohort is broad. The importance of the genetic 
predisposition to CAD is most likely highest in young ACS patients, so the GRS could 
serve best for the young. Assessing the multivariate model including GRS separately in 
patient subgroups according to age was not feasible due to lack of power. Additionally, 
individuals in the FINRISK study were younger than in the Corogene study. Some of 
these initially healthy FINRISK-cohort individuals are nevertheless likely to develop 
MI/PAD later in life.  
Although the follow-up of the study was complete, morbidities before study inclusion 
were recorded with insufficient precision to be informative in the data analyses. Some of 
the ACS patients had already had an MI before their inclusion in the Corogene study. For 
such patients, their ACS at study inclusion was actually a recurrent ACS. This fact 
possibly reduces the strength of the association between the GRS and recurrent ACS. 
Nevertheless, this was taken into account in the multivariable analysis concerning GRS 
and recurrent ACS association by adjustment of the analysis for prior MI in Study II. In 
Study IV, information on confirmed PAD diagnosis before study inclusion was 
unavailable. Thus, although the self-reported claudication symptoms at study inclusion 
were noted, such symptoms are not a confirmed sign of PAD. Instead, some of these 
patients may have another reason than PAD for claudication, leading to errors in the 
classification into incident or prevalent PAD. Since patients with PAD are generally very 
likely to have at least one PAD-related contact with health care during any 5 years, the 
likelihood of false negatives during the 5-year follow-up is, however, minimal.  
The GRSs of this study do not include the 10 risk SNPs found by the latest large meta-
analysis,159 nor are these SNPs tested for any association with STEMI/NSTEMI, ACS 
recurrence, or CAD mortality. Of the studies concerning associations between GRSs and 
recurrent ACS, however, the GRSs created for the Corogene study include the highest 
number of established CAD risk variants to date. 
 
6.6. Clinical implications and future perspectives 
 
Although the results of this study lack direct clinical implications, they raise several new 
questions and possibilities.   
ACS treatment involves several drugs. Previously clopidogrel and prasugrel, today 
most often tikagrelor, serve as standard antiplatelet therapy. Some genetic variants 
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predispose, however, to incomplete efficacy of these drugs.202 Additionally, some genetic 
variants impair the action and activity of statins, which are essential in secondary 
prevention therapy, and are thus related to increased risk for adverse effects such as 
myopathy.79,120 Thus far, testing of pharmacogenetic variants has not been a part of 
everyday clinical practice. Although the risk score, formed of CAD variants in this study, 
was associated with recurrent MI, it did not improve the prediction clinically 
significantly. Instead, a GRS combining both CAD risk variants and pharmacogenetic 
variants or only pharmacogenetic variants may prove more useful in risk prediction and 
merits investigation.  
Recurrent ACS may result either from occlusion of a stent or from further obstruction 
of the coronary arteries in sections that are not covered with a stent. Stent obstruction may 
result from stent thrombosis or from in-stent restenosis.29 Mechanisms of in-stent 
restenosis include neoatherosclerosis, prolapse of the disrupted plaque, elastic recoil of 
the vessel wall, constrictive remodeling, neointimal hyperplasia, or a combination of 
these processes.29 Restenosis is reported in 30% of patients with a bare metal stent, while 
in patients with a drug-eluting stent, restenosis is only half as common.29 Both family 
history of CAD and some genetic variants, different from CAD variants, have been 
discovered to predispose a patient to in-stent restenosis.161,166,201 Nevertheless, the value 
of GRSs that include CAD risk variants in predicting in-stent restenosis remains 
unexplored. Additionally, since autophagy is also known to affect risk for restenosis, the 
DRAM2-related variant rs656843 may in theory predispose to restenosis, as well. Its value 
in prediction of risk of restenosis needs investigation.   
The usefulness of a GRS in prevention of CAD in the Finnish population is currently 
under study.58 At the moment, however, the GRSs by themselves or supplemented by 
clinical factors cannot be utilized in predicting or prevention of ACS recurrence in 
clinical practice. New CAD- and MI-risk variants are being discovered at an increasing 
pace, however. As the number of known risk variants increase, the variants should also be 
included in the CAD risk scores to detect any possible improvement in their prediction 
capability. Recently, a GRS including only CAD risk variants not acting through any 
known clinical risk factor proved useful in classification of individuals into low-risk and 
high-risk categories and targeting the statin therapy.106 Similarly, exclusion of those risk 
variants related to risk factors could also strengthen GRS’s ability to predict ACS 
recurrence and improve its prediction capability.  
In terms of clinical characteristics, patients with stable CAD resemble NSTEMI 
patients more than they resemble STEMI patients. Whether the DRAM2-related variant 
rs656843 is additionally related to stable CAD is of interest. Furthermore, confirming an 
association between ACS and a GRS in patients with stable CAD would help to target 
prevention even more accurately.   
Although DRAM2 expression has been shown in the left ventricle of the heart, in the 
tibial artery, and in skeletal muscle,122 its expression needs further characterization. 
DRAM2 expression could be measured in atherosclerotic plaque from a coronary or 
peripheral artery or from myocardial cells, to further confirm the association between 
rs656843 and PAD/NSTEMI and to evaluate its importance in their pathogenesis.  
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7. Conclusions 
 
The following conclusions can be drawn on the basis of these studies: 
 
1. This study evaluated the characteristics of a Finnish cohort of consecutive patients who 
underwent coronary angiography between 2006 and 2008. About half the patients were 
revascularized. It remains to be seen to what extent new techniques of CAD imaging can 
eventually substitute for the invasive diagnostic angiography, and whether the proportion 
of patients revascularized after invasive angiography will rise.  
 
2. The GRS with 47 confirmed CAD variants formed in this study includes the largest 
number of risk variants among studies concerning GRS in recurrent ACS prediction. This 
GRS was associated with recurrent ACS in a Finnish population of ACS patients. The 
GRS failed, however, to significantly improve accuracy of prediction by clinical factors 
alone. Smoking, with its inverse association with the GRS, may outweigh a genetic 
predisposition to CAD. 
 
3. Both clinical and genetic differences between STEMI and NSTEMI patients were 
studied, and GWAS analysis revealed variants, including rs656843, at a locus near 
1p13.3, to be associated nominally with NSTEMI. The GRSs’ inverse correlation with 
STEMI, the finding of a genetic variant nominally linked to NSTEMI, and the fact that 
patients with NSTEMI and STEMI present with differing clinical risk-factor profiles 
suggest that these ACS subtypes may have somewhat different etiology. 
 
4. The genetic variant rs656843 conferring the risk for NSTEMI was also associated with 
PAD in ACS patients. Heterogeneity in PAD phenotypes and genetics probably explains 
why this association could not be shown in a general population cohort, but only in a 
selected cohort of ACS patients.  
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